The Role of Prostaglandins in Different Types of Cancer

Álvaro Jara-Gutiérrez and Victoriano Baladrón *

Área de Bioquímica y Biología Molecular, Departamento de Química Inorgánica, Orgánica y Bioquímica, Facultad de Medicina de Albacete/CRIB/Unidad de Biomedicina, Universidad de Castilla-La Mancha/CSIC, C/Almansa 14, 02008 Albacete, Spain; alvaro.jara@alu.uclm.es
* Correspondence: Victoriano.Baladron@uclm.es; Tel.: +34-967-599-200 (ext. 2926); Fax: +34-967-599-327

Abstract: The prostaglandins constitute a family of lipids of 20 carbon atoms that derive from polyunsaturated fatty acids such as arachidonic acid. Traditionally, prostaglandins have been linked to inflammation, female reproductive cycle, vasodilation, or bronchodilator/bronchoconstriction. Recent studies have highlighted the involvement of these lipids in cancer. In this review, existing information on the prostaglandins associated with different types of cancer and the advances related to the potential use of them in neoplasm therapies have been analyzed. We can conclude that the effect of prostaglandins depends on multiple factors, such as the target tissue, their plasma concentration, and the prostaglandin subtype, among others. Prostaglandin D2 (PGD2) seems to hinder tumor progression, while prostaglandin E2 (PGE2) and prostaglandin F2 alpha (PGF2α) seem to provide greater tumor progression and aggressiveness. However, more studies are needed to determine the role of prostaglandin I2 (PGI2) and prostaglandin J2 (PGJ2) in cancer due to the conflicting data obtained. On the other hand, the use of different NSAIDs (non-steroidal anti-inflammatory drugs), especially those selective of COX-2 (cyclooxygenase 2), could have a crucial role in the fight against different neoplasms, either as prophylaxis or as an adjuvant treatment. In addition, multiple targets, related to the action of prostaglandins on the intracellular signaling pathways that are involved in cancer, have been discovered. Thus, in depth research about the prostaglandins involved in different cancer and the different targets modulated by them, as well as their role in the tumor microenvironment and the immune response, is necessary to obtain better therapeutic tools to fight cancer.

Keywords: prostaglandin; COX-1; COX-2; NSAIDs; cancer

1. Introduction
1.1. A Piece of History

In 1930, R. Kurzrok and C. C. Lieb demonstrated that the uterine endometrium contracted and relaxed rhythmically after exposure to semen [1]. In 1939, Ulf von Euler stated that this contraction was due to the action of an unknown unsaturated lipid, which he called prostaglandin [2]. Then, S. Bergstrom observed the effects of prostaglandin in humans [3]. Between 1962 and 1966, the team of S. Bergstrom and D. A. van Dorp reported having achieved the synthesis of PGE2 from arachidonic acid and to have discovered the crystalline structure of PGF2α and PGE2, which allowed the synthesis of prostaglandins in sufficient quantities to carry out pharmacological studies [4]. In 1971, J. R. Vane demonstrated that ASA (acetyl salicylic acid, aspirin) and non-steroidal anti-inflammatory agents inhibited the synthesis of prostaglandins [5]. For their research on prostaglandins, S. Bergstrom, B. Samuelsson, and R. Vane, received the Nobel Prize in Medicine and Physiology in 1982.
1.2. Structure of Prostaglandins

Prostaglandins (PGs) are a family of lipids of 20 carbon atoms derived from polyunsaturated fatty acids, especially arachidonic acid (AA). Carbon atoms C8-C12 form a cyclopentane ring, while carbons C1-C7 and C12-C20 constitute two parallel aliphatic chains (R1 and R2, respectively) [6,7]. PGs are not produced by specialized glands but by different types of cells in the body, acting as autocrine and paracrine messengers. In addition, their half-life is short. Along with thromboxanes, they are known as prostanoid lipids, and share the same carbon skeleton. In turn, they are part of a larger group called eicosanoids, along with leukotrienes, lipoxins and hydroeicosatheroid and epoxyeicosatrieneic acids [8].

Regarding the nomenclature of PGs, it is summarized as follows: the accompanying letter to the acronym PG indicates the components of the cyclopentane ring and its solubility in different solvents (A: unsaturated ketones, soluble in cold acetone; E: β-hydroxyketones, soluble in ether; F: 1.3-dioles, soluble in phosphate buffer); the numeric subscript indicates the number of double links present in parallel strings; and the symbolic subscript indicates other structural details (α: OH group of C9 located on the same plane as the ring of R1; β: OH group in a plane other than R1) [6,7,9].

1.3. Prostaglandin Synthesis

PGs derive from AA oxidation, a process catalyzed by enzymes called cyclooxygenases (COX) or PGH (prostaglandin H) synthetases. In humans, there are two isoforms, COX-1 and COX-2 [10–12]. Both share 60% of their amino acid sequence and have a similar three-dimensional structure, although COX-1 and COX-2 are encoded by different chromosomes (chromosomes 9 and 1, respectively) (2). COX enzymes are membrane proteins with a molecular weight of approximately 70–74 kDa and possess four protein domains: (1) amino-terminal signal peptide domain, which guides the protein to its destination in the membranes. This domain has a longer length and greater hydrophobicity in the COX-1 isoform; (2) dimerization domain, which allows the stability of the protein by means of disulfide bridges, which link it to the catalytic domain, and salt bridges; (3) membrane binding domain, formed by four amphipathic helices that allow its insertion into the lipid bilayer; (4) catalytic domain (carboxyl-terminal), which has two separate catalytic sites with different functions (peroxidase and cyclooxygenase activities). Within this catalytic domain, there is an arginine residue at position 120 (Arg120) essential for substrate binding and inhibitory NSAIDs (non-steroidal anti-inflammatory drugs) action in COX-1, but it does not seem to be as determinant in COX-2 [13–16].

The COX enzymes mature in the endoplasmic reticulum, and they are then transported and inserted into the cell membrane, forming functional homodimers, with an access channel that allows the entry of AA. Precisely, ASA acetylates a serine residue on the surface of the access channel, irreversibly preventing the passage of the substrate, thus stopping the chain of chemical reactions [17,18]. The COX-1 enzyme is constitutively expressed in most tissues of the human body and is responsible for regulating the basal homeostasis of prostanoid synthesis, whereas the COX-2 enzyme promotes the transient and inducible synthesis of these compounds when eventual physiological or pathological processes occur, responding to certain stimuli. Among these stimuli are interleukin 1 (IL1), fibroblast growth factor (FGF), tumor necrosis factor (TNF), bacterial lipopolysaccharide (LPS) and nuclear transcription factor NFκB [10]. However, basal expression of COX-2 has been demonstrated in the brain, testis, tracheal epithelium and in the macula densa region of the kidneys [10].

AA is a polyunsaturated acid consisting of 20 carbon atoms, found in the phospholipids of the cell membrane. By the action of different extracellular stimuli (bradykinin, adrenaline, thrombin, corticoids, among others), phospholipases A2 and C are activated in the first phase of prostaglandin synthesis [19]. Phospholipase A2 directly releases AA from the phospholipids phosphatidyl-choline and phosphatidyl-ethanolamine from the
cell membrane. Phospholipase C releases diacylglycerol (DAG) from phosphatidyl inositol, and from the DAG generated, AA is released through the action of the enzyme diglyceride lipase. AA then travels through the cytosol until it is metabolized by the cyclooxygenase pathway [20], which generates prostaglandins and thromboxanes (TXA), by the lipoxygenase pathway, generating leukotrienes (LTB) and lipoxins (LXA) [7], or by the cytochrome P450 pathway, generating hydroeicosatrienoic acids (HETE) and epoxyeicosatrienoic acids (EET) [21].

Since the focus of this review is on PGs and the COX pathway, the remaining two pathways of AA-derived products are briefly described below [22]. The lipoxygenase (LOX) pathway gives rise to LTB and LXA. The enzymes required for LOX synthesis are present in leukocytes, macrophages, and mast cells, while those required to form LXA are found in leukocytes and platelets. Hyperactivity of this pathway has been associated with rheumatoid arthritis, inflammatory bowel disease, allergic rhinitis, bronchial asthma, osteoarthritis, and atherosclerosis. On the other hand, the cytochrome P450 pathway allows obtaining the EETs thanks to the CYP2C (P450 arachidonic acid epoxygenase 2C) and CYP2J (P450 arachidonic acid epoxygenase 2J) enzymes, and the HETEs by means of the CYP4A (cytochrome P450 4A fatty acid omega hydroxylase) enzyme activity. From EETs, dihydroxyeicosatrienoic acids (DHETEs) are generated by the action of the soluble enzyme epoxide hydrolase (sEH). All these acidic compounds allow the maintenance of vascular homeostasis by acting as vasodilators or vasoconstrictors depending on which compound they are transformed into [8].

In the cyclooxygenase pathway, a series of reactions catalyzed by COX1/2 enzymes culminate in the synthesis of the different types of PG and TXA. First, peroxidation leads to prostaglandin G2 (PGG2), an unstable and short-lived product. Then, deperoxidation generates prostaglandin H2 (PGH2), a direct precursor of other PGs (PGE2, PGD2, PGI2) and thromboxanes such as TXA2, which are synthesized by different enzymes depending on the tissue and the physiological state [7].

1.4. Mechanism of Action of Prostaglandins. Transport and Degradation

PGs cross the cell plasma membrane of cells into the extracellular medium by facilitated diffusion. PGs are anions at physiological pH, and as the intracellular voltage is about 20 times more negative inside the cell than outside, the tendency is to exit to the extracellular space. In addition, there is a concentration gradient of PGs; inside the cell their concentration is higher than outside, thus favoring their outflow. The magnitude of the effects of PGs depends not only on their synthesis, but also on their degradation, preferentially in the lung. The elapsed time until they are catabolized is usually seconds, preventing them from reaching the general circulation. Once they have fulfilled their function, PGs are carried into the cell by the prostaglandin transporter (PGT, SLCO2A1) [23]. Once inside, they are oxidized and inactivated by the enzyme 15-hydroxy-prostaglandin dehydrogenase (15-PGDH). The final product is eliminated in the urine [24].

Most of the actions of prostanoids are mediated by receptors coupled to different G (guanine nucleotide-binding protein) proteins that possess seven transmembrane domains and are encoded by different genes. Each of the prostanoids has at least one different receptor. Regarding PGs, eight different receptors have been described: two receptors for PGD2 (DP1 and DP2), four for PGE2 (EP1, EP2, EP3 and EP4), one for PGF2α (FP) and one for PGI2 (IP) [25]. The IP, DP1, EP2 and EP4 receptors mediate an increase in cAMP (cyclic adenosine monophosphate) and have been termed “relaxant-type receptors”, whereas the group composed of the FP and EP1 receptors associated with Gq (G protein heterotrimeric that activates beta isoforms of phospholipase C) induce calcium mobilization and are termed “contractor-type receptors”. In addition, FP receptors may be associated with RHO (RAS homologous GTPase protein) protein bound to small Gs (G protein that stimulates the cAMP-dependent pathway by activating adenylyl cyclase) protein via a Gq-independent pathway [26]. The DP2 receptor belongs to a different subgroup and is considered a member of the “chemoattractant receptors” subgroup. DP2 is associated
with inhibitory Gi (G protein that transmits an inhibitory signal from membrane receptors to adenylyl cyclase) protein inhibiting cAMP synthesis and increasing intracellular Ca\textsuperscript{2+} concentration. The EP3 receptor, formerly called “inhibitory receptor”, can bind to Gi or G12 (G protein that link cell surface G protein-coupled receptors primarily to guanine nucleotide exchange factors for the RHO small GTPases) and causes a decrease in intracellular cAMP levels, increases Ca\textsuperscript{2+} concentration and activates the RHO protein associated with a family of small G proteins [26].

1.5. General Functions of Prostaglandins

The prostaglandin functions depend on the organ or tissue, the receptor to which they bind, and the physiological situation. Broadly speaking, these functions are shown in Table 1. It could be concluded that they help to maintain homeostasis of the different organs/tissues and that they compose an alert system to normal and pathological physiological processes, giving rise to the appearance of inflammatory signs and pain, among many others [27].

| Biological System       | PG Mediator | Physiological Effect                                      |
|-------------------------|-------------|----------------------------------------------------------|
| Digestive system        | PGE\textsubscript{2}, PGI\textsubscript{2} | Reduction of acid secretion; Increase of mucous secretion |
|                         | PGE\textsubscript{2} | Longitudinal smooth muscle contraction; Circulatory smooth muscle contraction |
| Respiratory system      | PGL\textsubscript{2}, PGE\textsubscript{2} | Bronchodilator                                          |
|                         | PGH\textsubscript{2}, PGF\textsubscript{2α} | Bronchoconstriction                                      |
| Cardiovascular system   | PGE\textsubscript{2}, PGI\textsubscript{2} | Arterial vasodilation                                    |
|                         | PGF\textsubscript{2α} | Inhibition of platelet adhesion and leukocyte aggregation |
| Renal system            | PGI\textsubscript{2}, PGE\textsubscript{2} | Medullary blood flow, pressure diuresis                  |
|                         | PGE\textsubscript{2} | Renin release                                            |
|                         | PGE\textsubscript{2} | Natriuresis, diuresis                                    |
| Immune system           | PGE\textsubscript{2}, PGI\textsubscript{2} | Inhibition of proliferation and activation of T and B lymphocytes |
| Central nervous system  | PGE\textsubscript{2} | Inflammation                                             |
|                         | PGD\textsubscript{2}, PGI\textsubscript{2} | Induction of sleep                                       |
| Female reproductive system | PGE\textsubscript{2}, PGI\textsubscript{2}, PGF\textsubscript{2α} | Ovulation, implantation, endometrial contraction, and synergism with oxytocin |
| Male reproductive system | PGE\textsubscript{i}, PGE\textsubscript{3}, PGE\textsubscript{3}, PGF\textsubscript{2α} | Fertility |

1.6. Prostaglandin Inhibitors

There are different substances capable of preventing the formation of PGs by inhibiting COX1/2 enzymes [28]. These substances interact with specific amino acids of the enzymes to inhibit them. For example, ASA irreversibly binds to a serine-530 residue of the substrate entry channel, preventing the entry of arachidonic acid into the active site of COX1/2 enzymes that result irreversibly inactivated, especially COX1 [29,30]. Other drugs, such as ibuprofen and naloxen, act as competitive inhibitors of arachidonic acid and are more specific of COX2 enzyme [30]. For its part, indomethacin produces a time-dependent inhibition of both isoforms thanks to the electrostatic interaction between its carboxyl group and arginine-120 residue of the COX enzymes channel [31]. The presence of two valine amino acids in COX-2 (isoleucine in COX-1) allows some inhibitors to act selectively on COX2, thus avoiding the gastrointestinal and renal side effects typical of COX-1 inhibition [32]. Among the more selective COX-2 inhibitors, we find etoricoxib, lumaricoxib, nimesulide, among others.
2. Cancer and Prostaglandins

Previously, it has been mentioned that PGs are involved in a wide variety of biological processes. Within these processes, it is essential to include research on the involvement of these compounds in the development of different types of neoplasms, which is the objective of this review. We have revised many published works with interesting data about prostaglandins that are involved in different types of cancer, and we have described some of the latest therapeutic advances to treat cancer by acting on prostaglandins and enzymes related to these neoplasms.

2.1. Prostaglandins in Skin and Bone Cancer

Skin cancer most often develops on skin exposed to the sun, but it can also occur on areas of the skin not ordinarily exposed to sunlight. There are three major types of skin cancer: basal cell carcinoma, squamous cell carcinoma, and melanoma, which have different neoplastic characteristics, some of them related with prostaglandin actions.

In one study, a high expression of the enzyme aldo-keto reductase 1C3 (AKR1C3+) was found in skin squamous cell carcinoma, which reduces PGD2 levels by metabolizing it to PGF2α. This same study showed that PGD2 inhibits the formation of new vessels and, therefore, its reduction facilitates the neovascularization necessary for tumor progression [33].

Another study demonstrated that in this type of cancer, an increase in miR-31-5p micro–RNA is needed, which generates a decrease in acyl-coenzyme A peroxisomal A oxidase 1 (ACOX-1), an enzyme that favors normal concentrations of different lipids, including PGs. Suppression of ACOX-1 is associated with elevated PGE2 concentrations and increased tumor cell migration and invasion. In fact, it is proposed to use PGE2 concentrations in saliva as a biomarker of disease progression, since the higher the stage, the higher the concentration of PGE2 in saliva [34].

The treatment of squamous cancer and other cancer with 15-deoxy-delta-12,14-prostaglandin J2 (15d-PGJ2) has been shown to reduce cell growth, secondary to a lower concentration of the oncogenic STAT3 (signal transducer and activator of transcription 3) factor [35]. Similarly, it has been described that at higher concentrations of prostacyclin (PGI2), the 5-year survival rate in this type of cancer is higher. The increase of this prostaglandin would influence cell proliferation, cell migration and the inflammatory process [36].

A work carried out with mice showed that treatment of non-melanoma type cancer with apigenin, a compound found in fruits and vegetables, inhibits its progression. This substance produces inhibition of tissue polypeptide antigen (TPA), a tumor inducer driven by exposure to ultraviolet B (UVB) radiation, and a reduction in the concentration of COX-2, PGE1, and EP1 and EP2 receptors [37]. Another study has also demonstrated the efficacy of piroxicam as a preventive agent, as it also reduces COX-2 expression. Moreover, the local use of piroxicam on actinic keratoses and field cancerization has also been reported, confirming its efficacy as target therapy [38].

Elevated concentrations of PGF2α have also been found in melanoma tumor cells with respect to healthy tissues [35]. In cell and mouse models, this prostaglandin interferes with the mechanism of action of ASA. ASA blocks the expression of the sex-determining region of the Y chromosome (SRY) related to high mobility group 2 (SOX2), thereby promoting cell apoptosis. Increased PGF2α rescues such cells from cell death. Moreover, the use of antagonists of this prostaglandin potentiates the action of ASA [39].

Melanotan II (MTII), a synthetic analogue of the alpha-melanocyte stimulating hormone (alpha-MSH), potently inhibited the migration, invasion, and colony-forming capability of B16-F10 melanoma cells in vitro and in vivo despite a lack of influence on proliferation [40]. MTII treatment inhibited COX-2 expression and PGE2 production via PTEN (fosfatidilinositol-3,4,5-trisfosfato 3-fosfatasa) upregulation, thereby suppressing
melanoma progression. Hence, topical MTII therapy may facilitate a novel therapeutic strategy against melanoma.

On the other hand, overexpression of staphylococcal nuclease domain containing 1 (SND1) has been found in several malignancies including osteosarcoma, which is the most frequent primary bone tumor. Zhou and coworkers revealed that osteosarcoma tissues from different patients expressed significantly high SND1 mRNA and protein expression compared to normal bone tissues. They found that SND1 overexpression significantly promoted cell proliferation and tumor growth in vitro cell lines and in vivo. Their results also revealed that SND1 increased the production of PGE_2. The serum PGE_2 level had a significant positive association with the SND1 mRNA expression level in osteosarcoma tissues. Additionally, they found that SND1 upregulated PGE_2 expression through the NFκB/cyclooxygenase2 (COX2) pathway. Targeting of SND1 as a new antitumor strategy for patients with osteosarcoma and SND1 may also act as a potential biomarker of the therapeutic strategies utilizing COX2 inhibitors [41].

Recent studies showed that the activation of prostaglandin receptor EP1 promotes cell migration and invasion in different types of cancer, including osteosarcoma. Niu and coworkers investigated the role of EP1 in the proliferation of osteosarcoma cells in vitro and in vivo. EP1 levels were significantly higher in osteosarcoma cells compared to osteoblasts. PGE_2 or 17-PT-PGE_2 (17-phenyl-trinor-prostaglandin E2) treatment increased the proliferation and decreased the apoptosis of cells. Inhibition of EP1 by SC51089 or siRNA markedly decreased the viability of cells. EP1 appears to be involved in PGE_2-induced proliferative activity of cells. Antagonizing EP1 may provide a novel therapeutic approach to the treatment of osteosarcoma [42].

2.2. Prostaglandins in Breast Cancer

Breast cancer is a commonly reported cancer that is widely prevalent among women. Its early detection improves patient survival and results in better outcomes. For diagnosis and follow-up care, tumor markers are one of the feasible investigations to be ordered. 8-Iso-prostaglandin F_2α (8-iso-PGF_2α) serves as a serum non-invasive marker reflecting oxidative stress and subsequent damaging of DNA. The serum level of 8-iso-PGF_2α in the breast cancer patients (57.92 pg/mL) was significantly higher compared to those with benign tumors (18.89 pg/mL) (p < 0.001) [43].

Currently, a preventive treatment for this type of cancer is tamoxifen, which is only effective in cases of estrogen receptor (ER)-positive cells. A published review proposes the use of NSAIDs as chemopreventive agents for this type of cancer due to their multiple interactions with tumor development. NSAIDs inhibit tumor DNA synthesis, modulate ER concentration and the COX, NF-κB, caspases and WNT (wingless and Int-1)-β-catenin-TCF4 (transcription factor 4) pathways, as well as glycosegenesis, by inactivating 6-phosphofructose-1-kinase) [44].

The aldo-keto reductase (AKR) superfamily is gaining attention in cancer research. AKRs are involved in important biochemical processes and have crucial roles in carcinogenesis and chemoresistance. The enzyme AKR1C3 has many functions, which include production of prostaglandins, androgens and estrogens, and metabolism of different chemotherapeutics; AKR1C3 is thus implicated in the pathophysiology of different types of cancer, including breast cancer. The actions of AKR1C3 can produce FP receptor ligands whose activation results in carcinoma cell survival. 11β-Prostaglandin F_2α, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor, and induces slug expression in breast cancer [45]. It has been demonstrated that a high concentration of the PGF_2α-bound FP receptor is significantly (p = 0.02) related to a higher level of Ki-67 (nuclear protein related to cell proliferation) in AKR1C3+ breast cancer patients. Treatment of cells with an AKR1C3 inhibitor reduces PGF_2α levels comparable to those in healthy tissues. With squamous skin cancer, a study found that high concentrations of PGF_2α corresponded with a reduction in survival time. Moreover, it has been determined that this prostaglandin activates the ERK1/2-MAPK (extracellular signal-regulated kinase 1/2
mitogen-activated protein kinase) and NF-kB pathways by binding to the FP receptor, leading to increased resistance to chemotherapy treatment. This activation is slowed by using inhibitors of FP (AL8810) and NF-kB (BAY 11e7082 and Parthenolide) [45].

As described above, a study described the activation of the AKT (protein kinase B (PKB)-AP1 pathway in breast cancer by treatment with high concentrations of 15d-PGJ2. When this pathway is irregularly activated, it is normally modulated by the tumor suppressor PTEN, which acts by dephosphorylating PIP3 (phosphatidylinositol (3,4,5)-trisphosphate). This study demonstrated that prostaglandin 15d-PGJ2 covalently interacts with the cysteine-136 residue of PTEN and modifies it in such a way that it loses its ability to inhibit the AKT-AP-1 pathway [46]. On the other hand, some authors have shown that dichomo-γ-linoleic acid (DGLA) can act as an inhibitor of the COX-2 enzyme by inhibiting the enzyme delta-5-desaturase, which converts DGLA into arachidonic acid. Once inhibited, DGLA acts as a COX-2 substrate and is degraded to 8-hydroxyoctanoic acid that activates the caspases and poly-ADP-ribose polymerase (PARP) pathways. In addition, inhibition with DGLA has been shown to increase the efficacy of 5-fluorouracil treatment, which decreases tumor migration and invasion [46].

A recent study has shown that the increased concentration of the PGE2-EP2 complex limits the expression of the membrane protein CD80 (cluster of differentiation 80) in macrophages, which hinders macrophages polarization and the immune system (IS) response to cancer in human and mouse cells. Knock-out mice of microsomal PG synthetase 1 (mPGES-1) eliminates this limitation [47]. On the other hand, an in vivo experiment with different mouse models showed that ibuprofen reduces PGE levels and tumor volume in a dose-dependent manner, associated with an increase in mature macrophages, increased recruitment of CD45 (leukocyte common antigen) T lymphocytes, and decreased numbers of immature monocytes [48].

The results of a case-control study with human breast cancer patients in a phase-II randomized trial suggest that the perioperative use of β-antagonists such as propranolol, and COX-2 inhibitors such as etodolac, can significantly block STAT and EGR3 (early growth response protein 3) pathways, which would favor tumor dissemination. Regarding cellular activity, an increase in NK (natural killer) lymphocytes and B cells associated with a lower number of monocytes. Also, plasma interleukin 6 (IL-6) levels decreased [49].

In inflammation-associated carcinogenesis, COX-2 is markedly overexpressed, resulting in accumulation of various prostaglandins with oncogenic potential such as 15d-PGJ2. The epithelial-to-mesenchymal transition (EMT) is a process by which epithelial cells lose their polarity and adhesiveness, and thereby gain migratory and invasive properties. Treatment of human breast cancer MCF-7 cells with 15d-PGJ2 induced EMT as evidenced by increased expression of Snail (zinc finger transcriptional repressor) and ZEB1 (zinc finger E-box-binding homeobox 1), with concurrent down-regulation of E-cadherin and production of CXCL8 (chemokine (C-X-C motif) ligand 8) as a putative activator of fibroblasts, which may contribute to tumor-stroma interaction in inflammatory breast cancer microenvironment [50].

On the other hand, it is known that the formation of new blood (angiogenesis) and lymphatic (lymphangiogenesis) vessels are major events associated with most epithelial malignancies, including breast cancer. Inflammation is a key mediator of angiogenesis and lymphangiogenesis with aberrant expression of COX2, which is a major promoter of both events by the activation of prostaglandin E receptor EP4 on tumor cells, and the induction of oncogenic microRNAs. The COX-2/EP4 pathway also promotes additional events in breast cancer progression, such as cancer cell migration, invasion, and the stimulation of stem-like cells. EP4 antagonists hold a major promise in breast cancer therapy in combination with other modalities including immune check-point inhibitors [51].

### 2.3. Prostaglandins in Lung Cancer

Lung cancer, also known as lung carcinoma, is a malignant lung tumor characterized by uncontrolled cell growth in lung tissues. This growth can spread beyond the lung by
the process of metastasis into nearby tissue or other parts of the body. Most cancer that starts in the lung, known as primary lung cancer, are carcinomas. The two main types are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC).

Long-chain acyl-CoA synthetase (ACSL3) channels AA into phosphatidylinositol to provide the lysophosphatidylinositol-acyltransferase 1 (LPIAT1) with a pool of AA to sustain high prostaglandin synthesis. By using lung cancer cell lines, mouse models, some authors show that the LPIAT1 knockdown suppresses proliferation and anchorage-independent growth of non-small cell lung cancer by using cell lines and hinders in vivo tumorigenesis. In primary patient-derived frozen lung adenocarcinoma samples, the expression of LPIAT1 is elevated compared with healthy tissue and predicts poor patient survival [52].

TNF-α (tumor necrosis factor alpha) has been confirmed to promote tumor growth in laryngeal carcinoma. A work found a crosstalk between PGE2 and TNF-α signaling pathways, and the interaction between GRK2 (G-protein-coupled receptor kinase 2) and TRAF2 (TNF receptor associated factor 2), which leads to the activation of TNF-α–TRAF2–MMP (cell matrix metalloprotease)-9 signaling, and results in the progression of laryngeal carcinoma [53].

It has been shown both in lung and esophageal cancer cell lines and lung adenocarcinoma biopsy samples a link between activation of the CRTC1 (CREB-regulated transcriptional coactivator 1) oncogene, inactivation of the tumor suppressor LKB1 (hepatic kinase B1), and the presence of glycosylated COX-2 in pulmonary adenocarcinoma. CRTC1 potentiates the cAMP/CREB (transcription factor that binds to DNA sequences “cAMP response elements”) intracellular signaling pathway, which promotes tumor development. By using COX-2 inhibitors such as niflumic acid (NS-398), tumor growth was reduced in CRTC1+/LKB1− cases. The glycosylated COX-2-synthesized prostaglandin PGE2 binds to the EP2 y EP4 receptors and causes dephosphorylation of CRTC1, which in turn leads to increased COX-2 activation [54].

Other authors have found that high levels of the microRNA miR-574-5p are related to elevated concentrations of the prostaglandin PGE2 both in lung adenocarcinoma cell line and lung non-tumor and tumor tissue samples. This microRNA acts as an inhibitory substrate of the ARN1-binding protein in the CUG triplet repeat (CUGBP1), which under physiological conditions suppresses PGES-1 (PG synthetase 1). Furthermore, the upregulation of this microRNA is associated with high serum levels of interleukin 1β (IL-1β), typical in cases of non-small cell lung cancer with poor prognosis. The use of PGES-1 inhibitors abrogates the effect of miR-574-5p [55].

On the other hand, it has been shown that treatment of human non-small cell lung cancer cells with prostaglandins 15d-PGJ2 and PGD2 results in increased apoptosis due to increased ROS (reactive oxygen species) synthesis and activation of the caspases pathway [34]. Also, overexpression of the enzyme prostacyclin synthetase (PGIS) in lung cancer cell lines and mouse models has been shown to inhibit MHC-II (major histocompatibility complex-II+) lung cancer growth, independently of PGIs, through recruitment of T-CD4 (cluster of differentiation 4+) lymphocytes [56].

A randomized clinical trial with 5888 patients demonstrated that the use of NSAIDs leads to a reduction in lung tumor mass and fewer metastases [57]. Also, a retrospective case-control analysis to determine the effect of NSAID use on the incidence of lung cancer identified 1038 patients with lung cancer from a review of pathology data at several large hospital centers. The study suggested that smokers who regularly use NSAIDs might benefit from a possible protective effect against lung cancer [58].

2.4. Prostaglandins in Liver Cancer

There is a well-known relationship between the appearance of hepatocarcinoma and the proliferation of stellate cells. Stellate cells produce a dysregulation of the immune system, generating a decrease in regulatory T lymphocytes and an increase in myeloid-derived suppressor cells (MDSC), which favors tumor progression.
One study performed with cell lines and mouse models confirmed that the increase in stellate cells is due to increased activation of the COX2-PGE2-EP4 pathway in these cells [59]. These authors used COX-2 inhibitors such as SC-236 to inhibit the accumulation of stellate cells and stop the spread of liver cancer. The use of EP4 inhibitors, such as AH23848 was also effective, but only in in vitro tests.

Another study showed that prostaglandin PGE increases MYC (myelocytomatosis and tumor transcription factor) oncogene concentration by activating the EP4-protein-G-Adenylate cyclase-cAMP-kinase A-CREB pathway. This increase is not sufficient to trigger the onset of cancer, but it does facilitate its spread [60].

2,5-Dimethylcelecoxib (DMC) is a targeted inhibitor of mPGES-1, a key enzyme in the PGE2 synthesis pathway of inflammatory mediators and the inhibition of growth of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). DMC promotes HBV-related HCC immune microenvironment, which not only enrich the relationship between inflammatory factors (mPGES-1/PGE2 pathway) and the immunosuppression programmed death-ligand 1 (PD-L1), but also provide an important strategic reference for multitarget or combined immunotherapy of HBV-related HCC. By using mouse models and human tissue samples, these authors demonstrated that DMC combined with atezolizumab had more significant antitumor effect and stronger blocking effect on PD-L1 pathway [61].

2.5. Prostaglandins in Digestive System and Pancreas Cancer

Digestive cancer can develop along the entire digestive tract (esophagus, stomach, small intestine, large intestine, anus) as well as in other organs, such as the liver, pancreas, and biliary tracts. Among them, the number of colorectal cancer patients is increasing worldwide.

In a study based on human patients with esophageal squamous cancer, an elevated level of a subtype of Zinc transporter ZIP5 was observed. Inhibition of ZIP5 reduces metastasis and levels of cyclin D1 and COX-2 [62]. Host immunity plays a vital role in tumorigenesis, including tumor invasion and metastasis. The enzyme 15-PGDH, which plays a key role in prostaglandin degradation, is a critical inflammatory mediator in gastric cancer tumorigenesis. A study with gastric carcinoma patients demonstrated that 15-PGDH may contribute to anti-tumor immunity by regulating FOXP3 (fork head box protein 3) [63]. Also, a study with 277 patients showed that the presence of the prostaglandin PGD2 reduces tumor expansion of gastric adenocarcinoma by inhibiting the peroxisome proliferator-activated receptor gamma (PPARγ) pathway [36]. An interesting study proposes a connection between Helicobacter pylori infection and the development of gastric adenocarcinoma. Infection triggers an increase in COX-2 concentration, which favors the onset of tumor expansion. Prophylaxis based on the use of NSAIDs has been shown to be effective, considering the risk of gastro- and cardiotoxicity. In addition, it has been confirmed that the use of selective cyclooxygenase type 2 inhibitors (COXIB) can stop this gastric adenocarcinoma growth [62].

COX-2, activated in response to inflammatory stimuli, is also one of the major molecules that is involved in the development and progression of colorectal cancer. It has been shown that COX-2 inhibitors prevent the carcinogenesis and help in the treatment of sporadic or familial cases as shown by an overall increase in the survival rate. However, prolonged use of these inhibitors is associated with an increase in the risk of development of cardiovascular complications [64]. One study performed with cell lines, human tissues and mouse models showed that upregulation of the co-activator CRTC1 stimulates expression of the COX-2 gene and the production of prostaglandin PGE2, which in turn leads to dephosphorylation and activation of CRTC1, closing the feedback loop that increases tumorigenicity of colorectal cancer [65]. Another study performed in cell lines proposes that the XRCC5 (X-ray repair cross complementing 5) protein, involved in DNA repair and telomere maintenance, and the transcription factor p300, which phosphorylates the
XRCC5 gene, potentiate COX-2 expression. XRCC5/p300/COX-2 pathway could be a new therapeutic target since the use of p300 inhibitors seems to reduce COX-2 expression [66].

Several case-control and cohort studies demonstrate that continued prevention with ASA reduces the incidence of adenomas and mortality from this colorectal cancer. The effects of ASA begin to be significant after 3 years from the start of the treatment and with doses between 75 and 325 mg/day, with a greater impact on the proximal region of the colon [67]. A randomized clinical trial with 14,743 patients demonstrated that the use of NSAID s achieves a reduction in tumor mass and a lower number of metastases in this type of cancer [57]. Similarly, another study with stage III patients treated with ASA resulted in a decrease in mortality and neoplastic recurrence of colorectal cancer [62]. In addition, patients receiving combined treatment with ASA and statins were found to have lower levels of PG compared to those receiving only one of the treatments [68]. Another study with mouse models suggests that the use of sulindac in 15-PGDH knockouts could be a better alternative to other NSAIDs, since it reduces the number of new adenomas in the colon, although it is associated with greater inflammatory lesions in the proximal colon. Also, the knock-out of 15-PGDH has been associated with increased resistance to aspirin and celecoxib [69]. Finally, the treatment of colorectal cancer tumor cells with IP6 (inositol hexaphosphate) decreases COX-2 mRNA expression and activates genes of the lipoxygenase pathway, which reduced the concentration of PGE2 [70].

On the other hand, a study in different cell lines demonstrated that treatment with inhibitors of the PGE2-EP4 complex reduces the formation of new adenoma-like premalignant lesions in the colon, with reduced activation of the PI3K (phosphatidylinositol 3-kinase)-AKT-mTOR (muscular target of rapamycin) and ERK1/2-MAPK signal transduction pathways [71]. The prostaglandin PGF2α has been shown to reduce the migration and invasiveness of colorectal tumor cells [45]. However, the treatment of cells with 15d-PGJ2 results in the inhibition of telomerase, through modulation of the MYC oncogene, which directs these cells to a state of senescence or cell death [35]. A genetic study with cell lines and immunodeficient mice showed that tumor progression in colorectal cancer is related to the overexpression of the enzyme prostaglandin synthase E, due to an increase in the EGR1 (early growth response protein 1) factor, produced by the action of prostaglandin PGF2α. When a PGE2 receptor antagonist was used, EGR1 and PGE2 concentrations were reduced [72]. It has been also proposed that the urinary PG urinary metabolite (PGM) may be an early diagnostic marker of colon cancer, since its levels are higher in patients already diagnosed with this pathology, followed by patients with multiple adenomas [73].

Accumulating evidence has shown that the tumor microenvironment, including macrophages, neutrophils, and fibroblasts, plays an important role in the development and progression of colorectal cancer. Although targeting the TME could be a promising therapeutic approach, the mechanisms by which inflammatory cells promote colorectal cancer tumorigenesis are not well understood. Therapies targeting the specific downstream molecules of PGE2 signaling could be a promising approach [74].

As commented above for colon cancer, a study in different cell lines, including human pancreatic carcinoma cell line PANC-1, demonstrated that prostaglandin E2 activates the mTORC1 pathway through an EP4/cAMP/PKA- and EP1/Ca2+-mediated mechanism [71]. The pancreatic tumor stroma is composed of phenotypically heterogeneous cancer-associated fibroblasts with both pro- and anti-tumorigenic functions. Calcipotriol decreased cancer-associated fibroblasts proliferation and migration and reduced the release of the pro-tumorigenic factors such as prostaglandin E2 in cancer-associated fibroblasts (CAFs) isolated from human pancreatic tumor tissues. However, calcipotriol promoted PD-L1 upregulation, which could influence T cell mediated tumor immune surveillance and T cell activation [75]. Vitamin D3 analogues appear to have dual functions in the context of pancreatic cancer, which could have important clinical implications.

Several studies have shown that pancreatic cells do not express COX-1, which explains why ASA does not adequately prevent disease progression. Therefore, selective COX-2 inhibitors, such as COXIB-2 (celecoxib), should be used to reduce elevated COX-2
activity. However, COXIB-2 inhibitors have not demonstrated comparable efficacy to cisplatin and gemcitabine as a treatment for this type of cancer [62].

2.6. Prostaglandins in Renal and Urinary Cancer

Almost all kidney cancers are renal cell carcinomas. Most solid kidney tumors are cancerous, but purely fluid-filled tumors (cysts) generally are not. Exposure to cadmium (Cd) is considered to be a threat to human health. The kidney is the main target of Cd accumulation, which increases the risk of renal cell carcinoma. Shi and coworkers suggested that cells exposed to low dose Cd promoted migration of renal cancer cells, which was not dependent on Cd-induced reactive oxygen species (ROS) and intracellular Ca^{2+} levels. Cd exposure induced cAMP/PKA-II (protein kinase A type 2)-COX2, which mediated cell migration and invasion, and decreased expressions of the EMT marker, E-cadherin, but increased expressions of N-cadherin and Vimentin. This study might contribute to understanding of the mechanism of Cd-induce progression of renal cancer and future studies on the prevention and therapy of renal cell carcinomas [76]. It has also been shown that the higher the expression of COX-1, the higher the degree of malignancy of the renal tumor [36].

The use of 15d-PGJ2 in patients undergoing radical nephrectomy for renal cell carcinoma caused apoptosis of tumor cells through the caspases pathway and the activation of JNK (c-Jun N-terminal kinase) and AKT kinases, associated with an increase in intracellular calcium, and independently of the activation of the PPAR\gamma pathway [35]. In another study with 20 patient samples, higher PGE2 levels were observed in renal carcinoma samples compared with non-neoplastic renal parenchyma. However, these levels were not related to tumor size, Fuhrman grade, TNM (classification of malignant tumors and the extent of spread of cancer) stage, or histological subtype [77].

The most common of all upper urinary tract cancer are those found in the renal pelvis and renal calices. Cancer in the ureters makes up about a quarter of all upper urinary tract cancer. Tumors of the renal calices, renal pelvis and ureters start in the layer of tissue that lines the bladder and the upper urinary tract. Bladder cancer is a common solid tumor marked by high rates of recurrence, especially in non-muscle invasive disease. Inhibition of COX enzymes by NSAIDs results in reduced PGE2 levels, which is related with reductions in the bladder cancer [78]. Clinical trials using NSAIDs to prevent recurrence have had mixed results, but largely converge on issues with cardiotoxicity.

2.7. Prostaglandins in Nervous System Cancer

Nervous system cancer is the second leading type of cancer in children, after leukemia. Cancer of the nervous system involves tumors that form in one or more parts of the nervous system. Neuroblastoma, extracranial solid tumor of the sympathetic nervous system, mainly affects young children. Neuroblastoma is a cancer located in the adrenal medulla nerve cells of the body or other nervous system tissues such as the adrenal glands, around the spinal cord or in the abdomen. Cancer-associated fibroblasts is the main source of prostaglandin E2 in neuroblastoma contributing to angiogenesis, immunosuppression, and tumor growth.

Some authors believe targeting of mPGES-1 in cancer-associated fibroblasts will be an effective future therapeutic strategy in fighting neuroblastoma [79]. Several clinical and experimental studies have demonstrated that regular use of aspirin (ASA) correlates with a reduced risk of cancer and that the drug exerts direct anti-tumor effects. ASA could be used as an adjunctive therapeutic agent in the clinical management of neuroblastoma, although its effects appear to be mediated by a COX-independent mechanism involving an increase in p21 and underphosphorylated retinoblastoma (hypo-pRb1) protein levels [80]. MicroRNA-137 (miR-137) plays an important role in the development and progression of many types of human cancer. miR-137 was frequently down-regulated in retinoblastoma tissues. MiR-137 suppresses the proliferation and invasion of retinoblastoma cells by
targeting COX-2/PGE₂. miR-137 could be used as a potentially effective therapeutic target for the treatment of retinoblastoma [81].

Cancer of the nervous system might also affect the retina and it is called retinoblastoma or may affect the optic nerve and it is known as optic nerve glioma. Glioma, which is a cancer that affects the brain stem, is the most common type of cancer accounting for 45% of all brain cancer. There has been observed a direct and proportional relationship between the concentration of prostaglandin PGE₂ and the degree of malignancy in glioma tumors. A higher concentration of PGE₂ is related to greater cell proliferation and lower survival. This PG binds to EP2 and EP4 receptors, thereby activating PKA-II, which in turn activates CREB protein [82]. It has also been observed that PGE-EP4 binding stimulates the catabolic tryptophan 2-3 dioxygenase (TDO) enzyme pathway, which promotes immunosuppression by decreasing macrophages activation. The use of EP4 inhibitors decreases TDO activity [83]. Regarding prostaglandin PGD₂, it has been shown that high doses slow tumor proliferation in glioma, but low concentrations seem to stimulate it [36]. On the other hand, it has been shown that the use of 15d-PGJ₂ in human neoplastic glioma cells produces an increase in cell death, secondary to an increase in ROS production and activation of the caspases pathway [35].

2.8. Prostaglandins in Immune Cancer

Dendritic cells (DC) differentiate in the presence of determined factors or situations recognized as harmful, such as the onset of cancer. From the same progenitor, these cells differentiate into classical DC (cDC) or plasmacytoid DC (pDC) depending on which transcription factors are expressed. A study with mice showed that prostaglandin PGE₂ synthesized in lymphoma cancer cells results in inhibition of ZBTB46 (zinc finger and BTB Domain Containing 46) factor expression (only expressed in cDC), thus preventing differentiation to cDC and favoring tumor expansion. In addition, the use of a COX-2 inhibitor, such as NS-398, resulted in functional cDC that reduced tumor burden [84].

Sperandio and coworkers demonstrated that treatment of multiple myeloma with 15d-PGJ₂ produced a reduction in tumor cell proliferation without affecting non-neoplastic cells both in vitro and in mice tumors. A dose-independent increase in apoptosis was also observed in this study, which is probably related to the increased ROS concentration found in 15d-PGJ₂-treated samples [85].

Acute lymphoblastic leukemia (ALL) develops in the bone marrow in the vicinity of stromal cells known to promote tumor development and treatment resistance. The COX inhibitor indomethacin prevents the ability of stromal cells to diminish p53-mediated killing of cocultured ALL cells in vitro, and in a xenograft animal model, possibly by blocking the production of PGE₂. PGE₂ released by bone marrow stromal cells might be a target for improved treatment of pediatric ALL. The indomethacin treatment increased the level of p53 in the leukemic cells, implying that COX inhibition might reduce progression of ALL by attenuating protective paracrine PGE₂ signaling from bone marrow stroma to leukemic cells [86]. Glucocorticoid resistance remains a clinical challenge in pediatric acute lymphoblastic leukemia where response to glucocorticoids is a reliable prognostic indicator. cAMP signaling synergizes with dexamethasone to enhance cell death in glucocorticoid-resistant human T-ALL cells. The EP4 receptor expressed in T-ALL cells and PGE₂ increases intracellular cAMP, potentiates glucocorticoid-induced gene expression, and sensitizes human T-ALL cells to dexamethasone in vitro and in vivo [87].

On the other hand, an experiment performed with mice showed that the apoptotic effect of selenium (Se) supplementation in leukemia cells depends on the concentration of 15d-PGJ₂, which were analyzed in serum samples. Se activates the PPARγ pathway in vitro and in vivo assays, which reduces STAT-5 (signal transducer and activator of transcription 5) levels and blocks the expression of the CITED2 (cAMP-responsive element-binding protein (CBP)) gene, one of the responsible genes for tumor quiescence [88].
2.9. Prostaglandins in Endocrine Tissue Cancer

Endocrine cancer is found in tissues of the endocrine system, which include the thyroid, adrenal, sexual glands, and pituitary glands. Pituitary adenomas are multifactorial intracranial neoplasms that impose a massive burden of morbidity on patients. A study demonstrated that COX-1 and COX-2 expression levels were increased in pituitary tumors from human patients, including non-functional pituitary adenomas, acromegaly, Cush- ing’s disease and prolactinoma compared with normal pituitary tissues. The level of PGE2 was consistent with COX enzymes expression in pituitary adenoma tumors compared with healthy pituitary tissue. These results may open new molecular targets for early diagnosis/follow up of pituitary tumor growth [89].

The cyclooxygenase-2 (COX-2)-prostaglandin E2 (PGE2) pathway with BRAF (ser- ine/threonine-protein kinase B-Raf) mutation was shown to promote PGE2 synthesis. A study shows that COX-2 plays a key role in prognosis of Middle Eastern papillary thyroid carcinoma patients, especially in BRAF-mutated tumors. They suggest the potential therapeu tic role of COX-2 inhibition in patients with BRAF-mutated papillary thyroid carcinoma [90]. It has been also observed that the use of prostaglandin 15d-PGJ2 on papilla ry thyroid cancer cells produces an increase in ROS due to the accumulation of intracellular iron, which triggers tumor cell apoptosis [36].

Regarding the male reproductive system, AKR1C3 protein appears to play a key role in androgen synthesis in prostate cancer cases. It has been shown that in AKR1C3+ cases, the concentration of 17β-HSD (17β-hydroxysteroid dehydrogenase) is high. This molecule can be blocked by androgen receptor (AR) antagonists, such as enzalutamide but in the final stage of this disease, this effect disappears due to the mutation of the target protein of the AR antagonist: TMPRSS2 (transmembrane protease, serine 2)-ERG (ETS (erythroblast transformation-specific)-related gene) [91]. Increased expression of AKR1C3 has also been associated with elevated concentrations of the prostaglandin PGF2α, which activates the MAPK pathway and inhibits the PPARγ pathway. All these events favor proliferation and tumor resistance of prostate cancer to radiotherapy. The use of indomethacin suppresses AKR1C3 and eliminates this resistance [92].

Prostaglandin PGE2 has been shown to increase the migration and invasiveness of the prostate cancer through activation of PI3K/AKT/mTOR and matriptase pathways. The use of COX-2 inhibitors such as CAY10404 and celecoxib has the opposite effect. In addition, prostaglandin 15d-PGJ2 acts as a tumor suppressor by inhibiting AR [93,94]. Finally, a cohort study with 50 patients showed that higher COX-2 levels were significantly associated with higher PSA (prostate-specific antigen), higher Gleason grade, worse prognosis, higher probability of relapse after treatment, and shorter survival time [95].

Endometrial and ovarian cancer represent most gynecological malignancies in developed countries. Personalized treatments for this cancer depend on identification of prognostic and predictive biomarkers that allow stratification of patients. A study evaluated the level of AKR1C3 in endometrial cancer and ovarian cancer and examined possible correlations between expression of AKR1C3 and other clinical and pathological data [96]. Thus, the expression of AKR1C3 was higher in endometrial cancer compared to ovarian cancer. In endometrial carcinoma, high AKR1C3 expression correlated with better overall survival and with disease-free survival. In patients with ovarian cancer, there was no correlation between AKR1C3 expression and overall and disease-free survival or response to chemotherapy. These results demonstrate that AKR1C3 is a potential prognostic biomarker for endometrial cancer. Another study showed that the binding of the prostaglandin PGF2α to its receptor favors the proliferation and migration of tumor cells in patients with endometrial cancer [45]. On the other hand, prostaglandin PGJ2 has been shown to have inhibitory effects on endometrial tumor cell proliferation [91].

It has been established that an increase in prostaglandin PGE2 provides ovarian tumor cells with increased resistance to chemotherapy [97]. There is a known link between low expression of RGS10 (regulator of G-protein signaling 10), a G-protein modulator of prostaglandin action, and increased resistance to chemotherapy treatment in ovarian
cancer. The loss of functional RGS10 results in an increase in COX-2 concentration and thus an increase in prostaglandin PGE2 synthesis, which leads to the conclusion that RGS10 inhibits COX-2. However, this inhibition seems to be independent of its action on G proteins, since when inhibitors of this protein were used, no increase in the concentration of inflammatory markers was observed, so that the specific mechanism of inhibition has not yet been fully determined.

Even though in general cancer cases an increase in COX-2 levels is more common, it is very interesting that in the case of ovarian cancer a higher concentration of COX-1 is observed, which is why it has been suggested as a biomarker for early diagnosis. It has been proposed to use COX-1 inhibitors such as [18F]-fluorin and [18F]-P6 as tracers to detect ovarian cancer when performing PET (positron emission tomography). Furthermore, it has been shown that the treatment effect is increased with plactaxol combined with a selective COX-1 inhibitor (SC-560). It can be concluded that COX-1 inhibitors favor chemosensitivity of ovarian cancer [98].

To identify biomarkers that could predict response or lack of response to conventional chemotherapy at the time of diagnosis of high grade serous ovarian carcinoma, a study showed that evaluation of PGD2 is an independent marker of good prognosis in this carcinoma [99]. On the other hand, infection by human papillomavirus (HPV) serotype 16 is associated with an increase in COX-2 synthesis, which may be related to cases of cancer associated with these infections [100].

2.10. Prostaglandins in Other Cancer

COX-2 is activated in response to inflammatory stimuli, and it can mediate its tumorigenic effect through various mechanisms, such as inducing cell proliferation, inhibition of apoptosis, and suppressing the host’s immune response. Furthermore, COX-2 can induce the production of vascular endothelial growth factors, hence, promoting angiogenesis. The ability of COX-2 inhibitors to selectively restrict the proliferation of tumor cells and mediating apoptosis provides promising therapeutic targets for cancer patients. It is believed that COX2 can promote the development and progression of head and neck cancer. Therefore, COX2 inhibitors could be promising therapeutic weapons to fight the cancer [101].

EMT and angiogenesis are crucial events for development of aggressive and often fatal oral squamous cell carcinomas. Both processes promote cancer progression and metastasis development, but while the former induces the loss of E-cadherin expression; the latter produces blood vessel neoformation and contribute to cell growth, tumor mass development, and dissemination. COX-2 decreases the expression of E-cadherin and leads to phenotypic changes in epithelial cells enhancing their carcinogenic potential. This study was performed by a tissue microarray of oral squamous cell carcinomas from human patients [102].

An experiment with 180 mice demonstrated the potential of an EP-4 receptor inhibitor such as GW627368X to reduce PGE2 expression in sarcomas treatment [103]. This treatment resulted in reduced tumor volume and weight, and induction of apoptosis with increased levels of BAX (BCL-2-like protein 4) and AIF (apoptosis-inducing factor) along with low levels of Mcl-1 (induced myeloid leukemia cell differentiation protein) and Bcl-2 (apoptosis regulator). Moreover, this treatment did not cause systemic toxicity, immunosuppression, or behavioral changes.

Fibroblasts induce a high expression of COX-2, which leads to increased synthesis of PGs that promote the secretion of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF), thus generating a continuous positive feedback. One study shows that the use of DAPS (2,5-diacetoxylxyphenylsulfonate), an inhibitor of FGF and VEGF secretion, stops angiogenesis and tumor cell expansion in mice [104].
2.11. Prostaglandins in Tumor Microenvironment and Metastasis

The main reason cancer is such a serious illness is because of its ability to spread in the body. Cancer cells can spread locally by moving within the surrounding normal tissue. Cancer can also spread regionally, to nearby lymph nodes, tissues, or organs, and it can also spread to distant parts of the body. When this happens, it is called metastatic cancer or metastasis. For many types of cancer, this is called stage IV cancer. The transformation of a tumor cell into a metastatic tumor cell probably involves transient or permanent genetic changes, which determine the expression of molecules with actions that favor or protect the mechanisms necessary for metastasis. The most frequent locations of metastases are the organs most irrigated by blood, such as the brain, lungs, liver, bones, and adrenal glands. There is also a tendency for certain tumors to spread in certain organs. For example, prostate cancer tends to spread through the bones. Likewise, colon cancer does so in the liver and stomach cancer in the ovaries in the case of women. The cancers that metastasize the most are the most frequent cancers such as breast cancer, lung cancer, melanoma, and colorectal cancer.

Tumorigenesis is a multistep biological process and many studies have been focused on the critical role of the tumor microenvironment (TME). The tumor microenvironment plays a major role in the ability of the tumor cells to undergo metastasis. Tumor cells along with a small proportion of cancer stem cells exist in a stromal microenvironment consisting of vasculature, cancer-associated fibroblasts, immune cells, and extracellular components.

A major player of tumors gaining metastatic property is the inflammatory protein COX-2. Several tumors show upregulation of this protein, which has been implicated in mediating metastasis in various cancer types such as of colon, breast, and lung. COX2 has been closely linked to the occurrence, progression, and prognosis of cancer in tumor microenvironment [105]. It has also been shown that an abnormally high expression of the COX-2 enzyme leads to an increase in the concentration of the different PG subtypes, which favor or hinder different aspects of carcinogenesis. 15-Deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) is a prostaglandin whose effects depend on its concentration and the cell type in which it is found. Its effects include a decrease in angiogenesis and favoring of the apoptosis process. Prostaglandin 15d-PGJ2 produces an increase in ROS through mitochondrial dysfunction, activation of NADPH (Nicotinamide adenine dinucleotide phosphate) oxidase and JNK, and inhibition of AKT, which favors tumor apoptosis through the TRAIL (TNF-related apoptosis-inducing ligand) pathway associated with an increase in the concentration of the DR5 receptor, through a mechanism independent of the PPARγ pathway [36]. This activates PI3K-Akt signaling in human breast cancer cells through covalent modification of the tumor suppressor PTEN at cysteine 136 [46]. One study has shown that PGE2 favors the angiogenesis process for the supply of oxygen and nutrients necessary for tumor progression. The use of 3-(3-methylthiophen-2-yl)-5-(3,4,5-trimethoxyphenyl) isoxazole (2b) showed significant inhibitory activity toward COX-2 and showed a good inhibition of tumor growth, peritoneal angiogenesis, and ascites formation in Ehrlich ascites carcinoma (EAC) cell mouse model [106].

Increased levels of ATP in the tumor microenvironment in response to cell death mediated by chemotherapeutic agents such as doxorubicin leads to increased COX-2 expression, which, in turn, affords migratory and invasive properties to the tumor. Anti-inflammatory drugs against ATP receptors is a potential opportunity to be explored as cancer therapeutics [107]. Recent epidemiological and clinical studies strongly support the assertion that vitamin D supplementation is associated with reduced cancer risk and favorable prognosis. Experimental results suggest that vitamin D not only suppresses cancer cells, but also regulates tumor microenvironment to facilitate tumor repression [108]. Another study with mice showed that an increased intake of omega-3 and omega-6 polyunsaturated fatty acids reduced tumor growth in the melanoma microenvironment, along with a lower concentration of prostaglandins PGE2 and PGE3 [109].
The hypothesis that the anti-inflammatory activity of NSAIDs should be based on COX inhibition is well established in multiple experimental models, and NSAIDs are one of the therapeutic tools used in the current clinical fight against cancer, combined with other therapies. Thus, COX-2 inhibitors can reduce inflammatory factors thereby regulating macrophage recruitment for activating the antitumor immune microenvironment; downregulating vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis; and inhibiting the PI3K/Akt signaling pathway to induce tumor cell apoptosis. However, further in-depth investigation of these drug is needed to maximize antitumor efficacy and minimize the side effects [110,111].

The molecular and cellular mechanisms that cancer cells use to spread to other organs are diverse and complex. Thus, activation of PPARγ serves as a key factor in the proliferation and invasion of breast cancer cells and it is a potential therapeutic target for breast cancer. Heme oxygenase-1 (HO-1) is induced and overexpressed in various types of cancer and is associated with features of tumor aggressiveness. Recent studies have shown that HO-1 is a major downstream target of PPARγ. Jang and coworkers suggest that 15d-PGJ2 inhibits MMP9 expression and invasion of breast cancer cells by means of a heme oxygenase-1-dependent mechanism. Therefore, PPARγ/HO-1 signaling pathway inhibition may be beneficial for prevention and treatment of breast cancer and its metastasis [112].

The host stromal mPGES-1 is involved in the accumulation of myeloid-derived suppressor cells (MDSCs) in metastasized lungs of prostate cancer in mice. mPGES-1 enhances tumor metastasis in mice by inducing accumulation of BM (bone marrow)-derived MDSCs. Selective mPGES-1 inhibitors might, therefore, represent valuable therapeutic tools for the suppression of this tumor metastasis [113]. Prostaglandin 15d-PGJ2 has the ability to decrease breast and renal cancer metastasis, since it produces a reduction in the synthesis of extracellular matrix proteins (MMP), such as MMP-2 and MMP-9, which minimizes the invasiveness of these tumor cells [35]. Also, less melanoma metastasis has been demonstrated in mice with elevated concentrations of PGD2 [36]. By contrast, another study with patients showed that a higher concentration of PGE2 is significantly related to a higher expression of metalloprotease-1 (MMP1), which facilitates the transfer of cancer cells through the hematouencephalic membrane, and with it, the appearance of brain metastasis of breast cancer [114]. Similarly, prostacyclin (PGI2) has been shown to have great relevance as a tool to stop the development of tumor metastases [115]. Finally, the use of intraoperative injections of Etodolac (a NSAID) and propranolol in mice has been shown to reduce the number of colon cancer liver metastases by activating NK cells. However, neither compound separately obtained significant results [116].

Cervical cancer metastasis results in poor prognosis and increased mortality, which is not separated from inflammatory reactions accumulated by PGE2. As a specific G-protein coupled PGE2 receptor, EP3 is demonstrated as a negative prognosticator of cervical malignancy. EP3 signaling pathway might facilitate the migration of cervical cancer cells through modulating uPAR (urokinase plasminogen activator surface receptor) expression. Therefore, EP3 and uPAR could represent novel therapeutic targets in the treatment of cervical cancer in advantaged stages [117].

The ability of the immune system to recognize and eliminate tumor cells is called immune surveillance. One of the functions of the immune system is to recognize and destroy tumor cells before they grow and form a cancer, as well as to eliminate tumors that have already formed. At first, the results of some experiments questioned the importance of immune surveillance, but today it is clear that the immune system reacts to many tumors. This knowledge has led to the immune response being seen as another therapeutic weapon in the treatment of cancer. MDSCs include immature monocytic (M-MDSC) and granulocytic (PMN-MDSC) cells that share the ability to suppress adaptive immunity and to hinder the effectiveness of anticancer treatments. In response to IFNγ (interferon gamma), MDSCs release the tumor-promoting and immunosuppressive molecule nitric oxide (NO), whereas macrophages largely express antitumor properties. A study
indicates that inhibition of the PGE2/p50/NO axis prevents MDSC-suppressive functions and restores the efficacy of anticancer immunotherapy [118].

Immune checkpoint inhibitors improve survival outcomes in metastatic melanoma and non-small cell lung cancer. Preclinical evidence suggests that overexpression of cyclooxygenase-2 (COX2) in tumors facilitates immune evasion through prostaglandin E2 production and that COX inhibition synergizes with immune checkpoint inhibitors to promote antitumor T-cell activation. COXi inhibitor used concurrently with immune checkpoint inhibitors in human patients significantly associated with longer time-to-progression and improved objective response rate at 6 months in patients with metastatic melanoma and non-small cell lung cancer compared with Immune checkpoint inhibitors alone [119]. Furthermore, COXi inhibitor use appears to reverse the negative prognostic effect of a high neutrophil-lymphocyte ratio by prolonging time-to-progression in patients with melanoma.

Resistance to immunotherapy is one of the biggest problems of current oncotherapeutics. White T cell abundance is essential for tumor responsiveness to immunotherapy, factors that define the T cell inflamed tumor microenvironment are not fully understood. Markosyan and coworkers demonstrated in mice that tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2) in pancreatic adenocarcinoma [120]. Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are pathologically activated neutrophils that are crucial for the regulation of immune responses in cancer. These cells contribute to the failure of cancer therapies and are associated with poor clinical outcomes. A work demonstrated that mouse and human PMN-MDSCs exclusively upregulate fatty acid transport protein 2 (FATP2). Thus, FATP2 mediates the acquisition of immunosuppressive activity by PMN-MDSCs and represents a target to inhibit the functions of PMN-MDSCs selectively and to improve the efficiency of cancer therapy [121]. The initiation of an intestinal tumor is a probabilistic process that depends on the competition between mutant and normal epithelial stem cells in crypts. Intestinal stem cells are closely associated with a diverse but poorly characterized network of mesenchymal cell types. One study performed in humans and mice demonstrates that initiation of colorectal cancer is orchestrated by the mesenchymal niche and reveals a mechanism by which rare pericryptal Ptgs2-expressing fibroblasts exert paracrine control over tumor-initiating stem cells via the druggable PGE2-PTGER4-YAP signaling axis [122].

Table 2 summarizes some of the data observed in the different studies analyzed, which could help to plan new research.

| Tissue/Organ | Type of Cancer and Scenario | Cellular-Molecular Factors/Therapeutics | Molecular/Cellular Effect | Physiological/Pathological Impact |
|--------------|-----------------------------|----------------------------------------|--------------------------|----------------------------------|
| Skin         | Squamous                    | AKR1C3+ PGD2 decrease. PGE2 increase   | PGF2α increase          | Promotion of neovascularization  |
|              |                             | 15d-PGJ2 Inhibition of STAT-3 pathway | PGE2 increases          | Reduction of cell growth         |
|              |                             | miR-31-5p ACOX-1 decrease. PGE2 increase | Higher 5-year survival rate | Increase of tumor migration and invasion |
|              | Non-melanoma                | Apigenin COX-2 and PGE2-EP1/EP2 decrease | PGE2 increase          | Possible biomarker of invasion?   |
|              |                             | Piroxicam COX-2 decrease               |                          | Inhibition of neoplastic progression |
|              | Melanoma                    | PGE2 PGE2 decrease, larger stage       |                          | Inhibition of tumor progression   |
|              |                             | PGF2α antagonist Inhibition of ASA blockade | Prevention of tumor apoptosis |
|              |                             | Topical Melanotan II                   | Inhibition of COX-2 expression and PGE2 production | Prevention of tumor apoptosis |
|              | Bones                       | SND1 Increase of PGE2                 | Antitumor strategy using COX2 inhibitors. |
### Potential biomarker of the therapeutic strategies

| Tissue/Organ | Type of Cancer and Scenario | Cellular-Molecular Factors/Therapeutics | Molecular/Cellular Effect | Physiological/Pathological Impact |
|--------------|----------------------------|----------------------------------------|--------------------------|-----------------------------------|
| Mammary gland | Breast cancer              | AKR1C3+ PGF2α FP and Ki-67 increase    | Increase of cell proliferation |
|              |                            | AKR1C3 inhibitor PGF2α decrease        | Reduction of cell expansion |
|              |                            | PGF2α-FP increase Activation of ERK1/2-MAPK pathway and activation of NF-κB | Increase of resistance to QT |
|              |                            | FP inhibitor Inhibition of ERK1/2-MAPK pathway | Reduction of resistance to QT |
|              |                            | NF-κB inhibitor Inhibition of NF-κB factor |
|              |                            | 15d-PGJ2 Activation of AKT-AP-1 pathway | Promotion of tumor expansion. |
|              |                            | 15d-PGJ2 Up-regulation of Snail and CXCL8 expression | Epithelial-to-mesenchymal transition (EMT). |
|              |                            | 8-iso-PGF2α Serum non-invasive marker | Oxidative stress and subsequent damaging of DNA |
|              |                            | C136S-PTEN (mutated) Not affected by 15d-PGJ2 | Resistant? |
|              |                            | DGLA Activation of caspases, PARP and COX-2 | Decrease of tumor migration and invasion. Greater efficacy of treatment with 5-fluouracil. |
|              |                            | PGE2-E2 increase CD80 decrease on macrophages | Reduced macrophage polarization |
|              |                            | PGE2m-1 Knock out PGE2-E2 decrease and CD80 increase Normal macrophage polarization |
|              |                            | PGI2 increase | Shorter survival time |
|              |                            | Ibuprofen PGE2 decrease | Less tumor volume (dose-dependent), more mature macrophages, more CD-45+ T-lymphocytes, and fewer immature monocytes |
### Inhibition of STAT and EGR3 pathways

| Treatment                        | Molecular/Cellular Effect | Physiological/Pathological Impact |
|----------------------------------|--------------------------|----------------------------------|
| Propanolol + Etodolac (Peri-QX) | Inhibition of STAT and EGR3 pathways | Less tumor dissemination, more NK lymphocytes, more B cells, fewer monocytes, and less IL-6. |
| Increase of stellate cells       | COX2-PGE2:EP4 increase   | Fewer regulatory T-lymphocytes, more MDSCs |
| SC-236 (COX-2 inhibitor)         | Stellate cells ** decrease | Stop the spread of cancer |
| AH23848 (EP4 inhibitor)          | EP4-G-Adenylate increase and activation of cyclase-cAMP-kinase A-CREB pathway and oncogene MYC | Facilitation of tumor expansion |

### Hepatitis B virus-related hepatocellular carcinoma (HCC).

| Treatment                        | Molecular/Cellular Effect | Physiological/Pathological Impact |
|----------------------------------|--------------------------|----------------------------------|
| Propanolol + Etodolac (Peri-QX) | Inhibition of STAT and EGR3 pathways | Less tumor dissemination, more NK lymphocytes, more B cells, fewer monocytes, and less IL-6. |
| Increase of stellate cells       | COX2-PGE2:EP4 increase   | Fewer regulatory T-lymphocytes, more MDSCs |
| SC-236 (COX-2 inhibitor)         | Stellate cells ** decrease | Stop the spread of cancer |
| AH23848 (EP4 inhibitor)          | EP4-G-Adenylate increase and activation of cyclase-cAMP-kinase A-CREB pathway and oncogene MYC | Facilitation of tumor expansion |

### Tissue/Organ, Type of Cancer and Scenario | Cellular-Molecular Factors/Therapeutics | Molecular/Cellular Effect | Physiological/Pathological Impact |
|--------------------------------------------|----------------------------------------|--------------------------|----------------------------------|
| Digestive system, Esophageal squamous cancer | ZIP5 inhibitor                        | Cyclin D1 decrease, COX-2 increase | Metastasis reduction |
| Gastric adenocarcinomas                    | H. pylori                              | COX-2 increase           | Promotion of the onset of neoplasia |
|                                            | NSAIDs                                 | Inhibition of COX         | Effective prophylaxis |
|                                            | PGD2                                   | PPARγ decrease           | Slower growth |
|                                            | 15-PGDH                                | FOXP3                     | Anti-tumor immunity |
| Adenoma                                    | EP4 inhibitors                         | Inhibition of PI3K-AKT-mTOR and ERK1/2-MAPK pathways | Reduction of the number of new adenomas |
|                                            | ASA as prophylactic (75–325 mg)        | Inhibition of COX         | Effective prophylaxis |
|                                            | Sulindac (15-PGDH knock-out)           | Inhibition of COX         | Effective prophylaxis |
| Colorrectal cancer                         | COX2                                   | Inhibition of COX2        | Prevention of carcinogenesis. Increase in the survival rate. Risk of cardiovascular complications with prolonged treatment |
| Targeting the TME                         | Downstream molecules of PGE2 signaling | Promising approach        | Increased migration and invasion |
|                                            | PGF2α                                  | MYC modulation and telomerase inhibition | Increased rate of cell death |
|                                            | 15d-PGJ1                               | MYC modulation and telomerase inhibition | Increased rate of cell death |
|                                            | CRTC1                                  | Increase of CREB/AP-1, COX-2 and aaPGE2 | Promotion of tumor development |
|                                            | IP6                                    | Decrease of COX-2 and PGE2 | Hindrance of tumor development |
|                                            | NSAIDS                                 | Decrease of COX-2 and PGE2 | Reduction of tumor mass and metastasis |
|                                            | AAS (Stage III)                        | Decrease of COX-2 and PGE2 | Lower mortality and relapses |
|                                            | AAS + Statins                          | PG decrease               | Promotion of tumor progression |
|                                            | PGF cf                                 | Decrease of EGR1 factor and prostaglandin synthase E enzyme | Promotion of tumor progression |
|                                            | PGF inhibitors                         | Decrease of EGR1 factor and prostaglandin synthase E enzyme | Hindrance of tumor progression |
| Tissue/Organ | Type of Cancer and Scenario | Cellular-Molecular Factors/Therapeutics | Molecular/Cellular Effect | Physiological/Pathological Impact |
|-------------|-----------------------------|-----------------------------------------|---------------------------|-----------------------------------|
| Pancreas    | Pancreatic cancer           | AAS                                     | Not very useful, since they do not express COX-1.            |
|             |                             | Celecoxib                               | COX-2 decrease            | Possible adjuvant treatment for cisplatin + gemcitabine? |
|             |                             | Vitamin D3 analogues: calcipotriol      | PD-L1 upregulation        | Decreased cancer-associated fibroblasts proliferation and migration. Reduced release of PGE2. |
|             |                             | 15d-PGJ:                                | Activation of caspases, and JNK and AKT kinases. Intracellular [Ca²⁺] increase | Promotion of apoptosis |
| Kidney      | Renal cancer                | COX-1 increase                          | Higher degree of malignancy |
|             |                             | PGE₂ increase                           | Not related to tumor size, Fuhrman grade, TNM stage or histological subtype. |
|             |                             | Cadmium                                 | Activation of cAMP/PAKII-COX2 pathway and N-Catherin expression | Mediated cell migration and invasion |
| Urinary system | Bladder cancer             | PGE₂-EP2                                | Increase of proliferation and decrease of survival |
|             |                             | PGE₂-EP4                                | Reduction of macrophage activation |
|             |                             | PGD₂ increases                          | Reduction of tumor proliferation |
|             |                             | PGD₂ decreases                          | Increase of tumor proliferation |
|             |                             | 15d-PGJ:                                | ROS and caspases increase | Increase of cell death |
|             |                             | ASA                                     | COX-independent mechanism involving an increase in p21 and underphosphorylated hypo-pRb1. | Adjunctive therapeutic agent |
| Neuroblastoma | Glioma                     | MicroRNA-137                            | Inhibition of COX-2/PGE₂ | Suppression of proliferation and invasion of apoptosis |
|             |                             | 15d-PGJ:                                | ROS increase via PPARγ decrease | Increase of angiogenesis and promotion of apoptosis |
| Multiple Myeloma |                | Increased intake of omega-3 and omega-6 polyunsaturated fatty acids | PGE₂ y PGE₃ decrease | Reduction of tumor growth |
| Immune system | Acute lymphoblastic leukemia (ALL) | Indomethacin                            | Avoid the stromal cells diminished p53-mediated killing, Blockage of the production of PGE₂ | Reduction of progression of ALL |
|             |                             | EP4 receptor                            | Increase of intracellular cAMP | Sensitizes human T-ALL cells to dexamethasone |
|             |                             | PGE₂                                    |                            |                                    |
|             | General Leukemia            | Selenium supplements                     | Activation of PPARγ. Inhibition of STAT-5 and CITED2 | Apoptotic effect |
|             |                             | 15d-PGJ:                                | Increase of ROS-NADPH oxidase. Activation TRAIL-JNK. |                        |
### Inhibition of AKT

| Tissue/Organ | Type of Cancer and Scenario | Cellular-Molecular Factors/Therapeutics | Molecular/Cellular Effect | Physiological/Pathological Impact |
|--------------|-----------------------------|----------------------------------------|---------------------------|----------------------------------|
| Lymphomas    |                             | PGE2, Factor ZBTB46 decrease           | Prevention of differentiation to cDC |
|              |                             | NS-398, PGE2 decrease and cDC increase | Tumor burden reduction    |

### Tissue/Organ Type of Cancer and Scenario

| Type of Cancer and Scenario | Cellular-Molecular Factors/Therapeutics | Molecular/Cellular Effect | Physiological/Pathological Impact |
|-----------------------------|----------------------------------------|---------------------------|----------------------------------|
| Pituitary adenomas          | COX1/2 PGE2                            | Promotion of tumor progression |
| Papillary thyroid cancer    | 15d-PGJ2 [Fe2+] intracellular and ROS increase | Promotion of tumor apoptosis |
|                            | COX2 and PGE2                         | Promotion of tumor progression |
|                            | AKR1C3+                               | Increase of proliferation and resistance to radiation therapy |
|                            | 17β-HSD                               | Indomethacin suppresses AKR1C3 and eliminates resistance |
| Prostate cancer             | PGE2-EP1/EP2                          | Increase of migration and invasion |
|                            | CAY10404 and celecoxib                | Decrease of migration and invasion |
|                            | 15d-PGJ2                               | Tumor suppressor |
|                            | COX-2 increase                         | More proliferation and migration |
|                            | PGF2α                                  | Better overall survival Prognostic biomarker |
|                            | AKR1C3+                                | Reduction of proliferation |
|                            | RGS10 decrease                         | More resistance to chemotherapy |
|                            | COX-2 and PGE2 increase                | Early diagnostic biomarker? |
|                            | COX-I *** increase                     | Trackers when performing a PET scan? |
|                            | COX-I inhibitors ([18F]-Fluorine y [18F]-P6) | Increased chemosensitivity |
|                            | SC-560                                 | Marker of good prognosis |
| Endometrial cancer          | AKR1C3+                                | COX-2 increase Related to the onset of cancer? |
|                            | PGJ2                                   | Modulation of uPAR expression Negative prognostic indicator of cervical malignancy |
|                            | RGS10 decrease                         | More proliferation and migration |
|                            | COX-2 and PGE2 increase                | Better overall survival Prognostic biomarker |
|                            | COX-I *** increase                     | Reduction of proliferation |
|                            | COX-I inhibitors ([18F]-Fluorine y [18F]-P6) | More resistance to chemotherapy |
|                            | SC-560                                 | Early diagnostic biomarker? |
|                            | PGD2                                   | Trackers when performing a PET scan? |
| HPV serotype 16 infection   |                                         | Related to the onset of cancer? |
| Cervical cancer             | PGE2 receptor, EP3                    | Modulation of uPAR expression Negative prognostic indicator of cervical malignancy |

### Other tissues

| Tissue/Organ | Type of Cancer and Scenario | Cellular-Molecular Factors/Therapeutics | Molecular/Cellular Effect | Physiological/Pathological Impact |
|--------------|-----------------------------|----------------------------------------|---------------------------|----------------------------------|
| Sarcoma      | GW627368X (EP4 inhibitor)   | BAX and AIF increase. Reduction of tumor volume and weight. Induction of apoptosis |
| Fibroblasts  |                             | MCL-1, BCL-2 and PGE2 decrease         | Increase of angiogenesis and tumor spread |
| DAPS         |                             | COX-2, PGE2, FGF and VEGF increase     | Increase of angiogenesis and tumor spread |
| Head and neck cancers | COX-2 | Various mechanisms Protumorigenic effect. COX-2 selective inhibitors |
| TME/Metastasis/Immune surveillance | | |
|-----------------------------------|---------------------------------|---------------------------------|
| Oral squamous carcinomas          | COX-2                           | Loss of E-cadherin expression   |
| All                               | COX-2. PGE\(_2\), ATP           | Increased angiogenesis          |
|                                   | Vitamin D                        | Decrease of cancer risk and favorable prognosis |
|                                   |                                  | Supply of O\(_2\) and nutrients. |
| Breast cancer                     | CXCL8                           | Activator of fibroblasts,       |
| Liver cancer                      | 2,5-dimethylcecloxicib (DMC)     | Promotion of HBV-related HCC immune TME |
| Pancreatic adenocarcinoma          | EPHA2                           | Suppression of anti-tumor immunity |
| PMN-MDSCs                         | Mesenchymal niche                | Initiation of colorectal cancer |
| Intestinal tumor                  | PGE\(_2\)                        | MMP1 increase                   |
|                                   |                                | More brain metastases          |
| Breast cancer                     | PGL\(_2\)                       |                                |
|                                   | 15d-PGJ\(_2\)                   | Inhibition of MMP9 through PPAR\(_γ/HO-1\) signaling pathway |
|                                   |                                | Prevention and treatment of breast cancer and its metastasis |
| Prostate cancer                   | mPGES-1                         | Accumulation of BM-MDSCs in lungs |
|                                   |                                | Use of Selective mPGES-1 inhibitors |
| Renal cancer                      | 15d-PGJ\(_2\)                   | MMP decrease                   |
| Melanoma                          | PGE\(_2\)                       | Reduction of invasiveness      |
| Melanoma and non-small cell lung cancer | COX1/2 inhibitors          |                              |
|                                   |                                | Lower number of metastasis     |
| Colorectal cancer                 | Etofolac + Propanolol           | Lymphocytes NK increase        |
| Immune System                     | Immune surveillance             |                              |
|                                   |                                | Therapeutic weapon to eliminate tumor cells |
| M-MDSC                            | Increase of NO                  | Suppression of adaptive immunity |
|                                   |                                | Inhibition of the PGE\(_2\)/p50/NO |

* After inhibiting the enzyme delta-5-desaturase (whose function is to convert DGLA into arachidonic acid). ** Only in vitro assays. *** Although in cancer COX2 is usually increased, in this case there is a very striking increase in COX-1.

3. Conclusions

According to the data revised in this work, the involvement and importance of PGs in the development of different neoplasms is more than evident. The effects of prostaglandin in cancer depends on multiple factors, such as the target damaged tissue, the plasma concentration of prostaglandins and their subtypes, and the presence of genetic mutations and the different intracellular signaling pathways involved, will tip the balance either towards tumor regression or cancer expansion.

Prostaglandins of the PGD\(_2\) type are clearly related to better survival expectations, since they can hinder tumor progression. In all the evidence reviewed, it can be observed that a higher concentration of the prostaglandin PGD\(_2\) is associated with a greater difficulty for the tumor to progress, either as a primary tumor or as metastasis, and with increased apoptosis of cancer cells. However, a low concentration of this prostaglandin does not protect against tumor development. Therefore, PGD\(_2\) can be considered as a protective factor against cancer and a marker of good prognosis.

PGE\(_2\) and PGF\(_{2\alpha}\) prostaglandins are related to greater tumor progression and aggressiveness, also associated with a worse functioning of the immune system. With respect to PGE\(_2\), all the references found seem to point to it as a prostaglandin that facilitates tumor development by activating different signaling pathways. The action of this prostaglandin results in greater vascularization, greater ease of metastasis, and less maturation of immune system cells capable of halting its advance, like macrophages polarization and activation, although it sensitizes human T-ALL cells to dexamethasone. Therefore, it could be said that a high amount of PGE\(_2\) is a risk factor to be considered in tumor origin and
progression. In fact, some of the authors propose using the measurement of its levels as a biomarker of neoplastic evolution. Everything seems to indicate that the prostaglandins PGF\(_{2\alpha}\) is one of the factors responsible for the resistance of different types of cancer to some of the therapeutic options, such as the use of ASA or chemotherapy. In addition, this prostaglandin has been related to a greater capacity for cancer migration and invasion and prevents tumor apoptosis. Therefore, elevated PGF\(_{2\alpha}\) concentration could be considered a risk factor for neoplastic progression. Also, PGF\(_{3\gamma}\) facilitates tumor progression in some neoplasms such as colorectal cancer.

Prostaglandins PGI\(_2\) and PGJ\(_2\) are generally related with the arrest of cancer development, but since works point them out as possible inducing factors of neoplasia, further research is necessary to clarify the contradictory data. Thus, there is some controversy in the implication of prostaglandin PGI\(_2\) in cancer. Most scientific works show data that may lead to the assumption that it acts as a protective factor against neoplastic development. Thus, high concentrations of PGI\(_2\) are related to a lower number of metastases of any type of cancer and a higher 5-year survival in squamous epithelial cancer by inhibiting lung tumor growth. However, one research work demonstrates a significant relationship between a high concentration of this PG and a lower survival in breast cancer. Therefore, determining the role of this PG in the development of cancer is risky, so it would be advisable to study its involvement in different types of cancer. As with prostaglandin PGI\(_2\), the data on the involvement of prostaglandin PGJ\(_2\) in cancer are also contradictory. Most of the works suggests that PGJ\(_2\) has the capacity to inhibit tumor expansion, as it seems to facilitate cancer cell apoptosis and hinder angiogenesis, proliferation, and invasion. However, some other researchers propose that PGJ\(_2\) may promote tumor progression by inhibiting the tumor suppressor PTEN activity in breast cancer.

In addition to the evidence found about the influence of the different subtypes of PGs on the distinct types of cancer, it is necessary to make special mention of the function of AKR1C3 protein that can determine the intensity of the effects of these lipid molecules on tumor development. The presence of this protein has been related to a shift from the synthesis of “potentially protective PGs”, such as PGD\(_2\), towards the synthesis of “potentially carcinogenic PGs”, such as PGF\(_{2\alpha}\). This shift leads to increased tumor vascularization and increased resistance to different therapeutic tools. For this reason, the AKR1C3 protein is proposed as a possible and interesting therapeutic target. In fact, in some of the studies reviewed, inhibitors of this enzyme are used, in which PGF\(_{2\alpha}\) levels are normalized and tumor expansion is slowed down.

The use of different NSAIDs, especially selective COX-2 inhibitors, may have a crucial role in the therapeutic strategy to end the origin and progression of neoplasms, either as a prophylactic treatment in the population at risk, or as an adjuvant treatment to chemotherapy or radiotherapy. Moreover, the analysis of the intracellular signaling pathways involved in cancer and related to the action of prostaglandins has revealed multiple therapeutic targets in addition to COX1/2 enzymes. Therefore, more detailed studies should be carried out to obtain better therapeutic tools by combining treatments against cancer.

Given the great relevance of PGs in terms of the outcome of neoplasms, it would be interesting to favor, by means of different genetic, biochemical, and molecular tools, the reduction of the concentration of “potentially carcinogenic PGs”, such as PGE\(_2\) and PGF\(_{2\alpha}\), and to increase the concentration of “potentially protective PGs”, such as PGD\(_2\), PGI\(_2\) and PGJ\(_2\). Therefore, both the inhibition of the expression of the genes that code for COX enzymes, and the use of specific inhibitors of these enzymes are good therapeutic strategies against cancer, since they would reduce the concentrations of the different types of PGs.

On the other hand, the scientific studies reviewed also consider other therapeutic possibilities, such as the use of PG receptor inhibitors. Despite the high concentrations of PGs that may be present in plasma in a neoplastic process, the inhibition of their receptors would avoid the binding of PGs to their receptors and PGs would not be able to produce any effect on the nearby cells, with the result that the PGs would be destroyed without having any repercussions. In addition, as described above, there are many signaling
pathways that interact with PGs. These interactions increase the number of possible therapeutic targets, since it would be possible to block these connections at more points, at the genetic, molecular, or cellular levels. Some examples of these potential targets analyzed are ZIP5, mPGES-1, FGF, VEGF, XRCC5, PPARγ, AKT, ERK1/2 MAPK, NFκB, PTEN, or p300, among many others.

Finally, as described above, the studies should be also focused on the critical role of the tumor microenvironment (TME) as a promoter of the ability of the tumor cells to undergo EMT and metastasis. One of the major players in metastatic tumors is the inflammatory protein COX-2 upregulated in several tumors, which lead to the production of PGs and the development of the different aspects of carcinogenesis. As mentioned through this revision, selective COX-2 inhibitors are preferred over an inhibitor of both isoforms to avoid the side effects of COX-1 suppression. COX-2 selective inhibitors produce a reduction of PGs together with the inhibition of tumor progression, either in extension or in the number of tumors. The hypothesis that the anti-inflammatory activity of NSAIDs should be based on COX inhibition is well established, and NSAIDs are one of the therapeutic tools used in current clinical fight to cancers, combined with other therapies. Another factor to consider in the fight against cancer is the immune surveillance or the ability of the immune system to recognize and eliminate tumor cells, which has been seen as another therapeutic weapon in the treatment of cancer.

It is important to clarify that data presented in this review, about the involvement of prostaglandins in the different types of cancer, are observations made in vitro assays, by using cell lines, in ex vivo assays, by using samples of tumorigenic tissues from animals or humans, or in vivo experiments, made in animals, but few molecular and cellular data have been confirmed in humans. Therefore, more detailed studies should be carried out in humans to confirm the molecular and cellular events observed in animals or cell lines, and to determine the appropriate concentrations of prostaglandins and their inhibitors to use in human patients in order to develop safe single or polytherapy tools against cancer, avoiding unwanted side effects as much as possible.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Data sharing not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

- Alpha-MSH: alpha-melanocyte stimulating hormone
- 8-iso-PGF2α: 8-Iso-prostaglandin F2 alpha
- 15d-PGj2: 15-deoxy-Delta (12,14)-prostaglandin J2
- 15-PGDH: tumor suppressor 15-hydroxyprostaglandin dehydrogenase
- 17β-HSD: 17β-hydroxysteroid dehydrogenase
- 17-PT-PGE2: 17-phenyltrinor-prostaglandin E2
- AA: arachidonic acid
- AC: Adenylyl cyclase
- ACSL3: long-chain acyl-CoA synthetase
- ACOX-1: acilcoenzyme A peroxisomal A oxidase 1
- AH23848: (4Z)-7-[(rel-1S, 2S, 5R)-5-((1,1′-Biphenyl-4-il) methoxy)-2-(4-morfolinil) 3-oxocyclopentenil]
- AIF: apoptosis inducer factor
- AKR: aldo-keto reductase enzymes
- AKR1C3: aldo-keto reductase enzyme 1 C3
- AKT: protein kinase B (PKB)
- ALL: acute lymphoblastic leukemia
- AML: acute myeloid leukemia
HCC hepatocarcinoma
HO-1 heme oxygenase 1
Hypo-pRb1 underphosphorylated retinoblastoma 1
GRK2 G-protein-coupled receptor kinase 2
HPV human papillomavirus
IFNγ interferon gamma
IL-6 Interleukin 6
IL-1β Interleukin 1β
IP PGi1 receptor
IP6 inositol hexaphosphate
IS immune system
JNK c-Jun N-terminal kinase
Ki-67 nuclear protein related to cell proliferation
LKB1 hepatic kinase B1. Serine-threonine kinase that directly phosphorylates and activates AMPK
LOX Lipoxygenase
LPS lipopolysaccharide
LPAT1 lysophosphatidylinositol-acyltransferase 1
LTB Leukotriene B
LXA lipoxin A
MCL-1 cell differentiation protein from induced myeloid leukemia
MCF-7 Michigan Cancer Foundation-7 cell line
MDSC myeloid-derived suppressor cells
MHC-II major histocompatibility complex-II
miR-31-5p microRNA-31-5p
miR-574-5p microRNA-574-5p
M-MDSC immature monocytic derived suppressor cells
MMP cell matrix metalloprotease
MTII Melanotan II
mTOR muscular target of rapamycin
MYC myelocytomatosis and tumor transcription factor
NADPH Nicotinamide adenine dinucleotide phosphate
NFκB nuclear transcription factor κB
NK cells natural Killer cells
NO nitric oxide
NS-398 nifluric acid
NSAIDs nonsteroidal anti-inflammatory drugs
NSCLC non-small-cell lung carcinoma
PARP poly-ADP-ribose polymerase
Farthenolide NF-κB inhibitor
PD-L1 programmed death-ligand 1
PET positron emission tomography
pDC plasmacytoid dendritic cells
PG prostaglandin
PGD2 prostaglandin D2
PGDH 15-hydroxy-prostaglandin dehydrogenase
PGE1 prostaglandin E1
PGE2 prostaglandin E2
PGE3 prostaglandin E3
mPGES-1 microsomal PG synthetase 1
PGES-1 PG synthetase 1
PGF2α prostaglandin F-2α
PGF2β prostaglandin F-2β
PGI1 prostacyclin
PGIS prostacyclin synthetase
PGM PG urinary metabolite
PGT/SLCO2A1 PG transporter
PGH2 prostaglandin H2
PI3K phosphatidylinositol 3-kinase
PIP2 phosphatidylinositol 4,5-bisphosphate
PIP3 phosphatidylinositol (3,4,5)-trisphosphate
PKA-II protein kinase A type 2
PLC phospholipase C
PMN-MDSC granulocytic derived suppressor cells
PPARγ peroxisome proliferator-activated receptor
PSA PROSTATE ANTIGEN
PTEN phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase
PTGER4 prostaglandin E receptor 4 [Homo sapiens (human)]
RGS10 Regulator of G-protein signaling 10
RHO Ras homologous GTPase protein
ROS reactive oxygen species
SC-236 4-[5-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide
SCLC small-cell lung carcinoma
Se selenium
sEH soluble enzyme epoxide hydrolase
Snail zinc finger transcriptional repressor
SND1 staphylococcal nuclease domain containing 1
SOX2 sex-determining region of Y chromosome (SRY)-related high-mobility-group box 2
SIK1/2 salt-inducible kinases 1/2
SRY sex-determining region of Y chromosome
STAT3 signal transducer and activator of transcription 3
TDO tryptophan 2,3-dioxygenase
TCF4 transcription factor 4
TMPRSS2 (Transmembrane protease, serine 2)
TNFα tumor necrosis factor Alpha
TNM stage classification of malignant tumors and the extent of spread of cancer
TPA tissue polypeptide antigen
TRAF2 TNF receptor associated factor 2
TRAIL TNF-related apoptosis-inducing ligand
TXA thromboxane A
TNF tumor necrosis factor
XRCC5 X-Ray Repair Cross Complementing 5
uPAR urokinase plasminogen activator surface receptor
UVB ultraviolet radiation B
VEGF vascular endothelium growth factor
YAP Yes1 associated transcriptional regulator
ZEB1 zinc finger E-box-binding homeobox 1
ZIP zinc Interacting Protein
ZBTB46 zinc finger and BTB Domain Containing 46
WNT wingless and Int-1

References
1. Raphael Kurzrok, C.C. Biochemical Studies of Human Semen. II. The Action of Semen on the Human Uterus. Proc. Soc. Exp. Biol. Med. 1930, 28, 268–272.
2. Igic, R. Remembrances of Ulf Svante von Euler. Acta Physiol. (Oxf.) 2018, 224, e13098, doi:10.1111/apha.13098.
3. Bergstrom, S.; Dunér, H.; von, E.U.; Pernow, B.; Sjovall, J. Observations on the effects of infusion of prostaglandin E in man. Acta Physiol. Scand. 1959, 45, 145–151, doi:10.1111/j.1748-1716.1959.tb01686.x.
4. Nugteren, D.H.; Van Dorp, D.A.; Bergstrom, S.; Hamberg, M.; Samuelsson, B. Absolute configuration of the prostaglandins. Nature 1966, 212, 38–39, doi:10.1038/212038a0.
5. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971, 231, 232–235, doi:10.1038/newbio231232a0.
6. Nagy, G. The prostaglandins. Ther. Hung. 1981, 29, 61–67.
7. Holdcroft, A. Prostaglandins—A review. Anaesth. Intensive Care 1975, 3, 105–113, doi:10.1177/0310057X7503002004.
8. Calder, P.C. Eicosanoids. Essays Biochem. 2020, 64, 423–441, doi:10.1042/EBC20Y90083.
9. Nelson, N.A. Prostaglandin nomenclature. J. Med. Chem. 1974, 17, 911–918, doi:10.1021/jm00255a001.
10. Crofford, L.J. COX-1 and COX-2 tissue expression: Implications and predictions. *J. Rheumatol. Suppl.* 1997, 49, 15–19.

11. Vane, J.R.; Bakhle, Y.S.; Botting, R.M. Cyclooxygenases 1 and 2. *Annu. Rev. Pharmacol. Toxicol.* 1998, 38, 97–120, doi:10.1146/annurev.pharmtox.38.1.97.

12. Smith, W.L.; DeWitt, D.L.; Garavito, R.M. Cyclooxygenases: Structural, cellular, and molecular biology. *Annu. Rev. Biochem.* 2000, 69, 145–182, doi:10.1146/annurev.biochem.69.1.145.

13. Williams, C.S.; Mann, M.; DuBois, R.N. The role of cyclooxygenases in inflammation, cancer, and development. *Oncogene* 1999, 18, 7908–7916, doi:10.1038/sj.onc.1203286.

14. Vane, J.R.; Botting, R.M. Anti-inflammatory drugs and their mechanism of action. *Inflamm. Res.* 1998, 47 (Suppl. S2), S78–S87, doi:10.1007/s000110050284.

15. Bennett, A. Anti-inflammatory drugs, cyclooxygenases and other factors. *Expert Opin. Pharmacother.* 2001, 2, 1–2, doi:10.1517/14656566.2.1.1.

16. Botting, J.H. Nonsteroidal antiinflammatory agents. *Drugs Today (Barc)* 1999, 35, 225–235, doi:10.1385/dtt:1999.35.4.5.552199.

17. Dannhardt, G.; Kiefer, W. Cyclooxygenase inhibitors—Current status and future prospects. *Inflamm. Res.* 2000, 3, 109–126, doi:10.1016/s0223-5234(01)01197-7.

18. Eschwege, P.; de Ledinghen, V.; Camilli, T.; Kulkarni, S.; Dalbagni, G.; Droupy, S.; Jardin, A.; Benoit, G.; Weksler, B.B. [Cyclooxygenase inhibitors]. *Presse Med.* 2001, 30, 515–517.

19. Simmons, D.L.; Botting, R.M.; Hla, T. Cyclooxygenase isoforms: The biology of prostaglandin synthesis and inhibition. *Pharmacol. Rev.* 2004, 56, 387–437, doi:10.1124/pr.56.3.3.

20. Hla, T.; Bishop-Bailey, D.; Liu, C.H.; Schaefer, H.J.; Trifan, O.C. Cyclooxygenase-1 and -2 isoenzymes. *Int. J. Biochem. Cell Biol.* 1999, 31, 551–557, doi:10.1016/s0065-9539(98)00152-6.

21. Panigrahy, D.; Kaipainen, A.; Greene, E.R.; Huang, S. Cytochrome P450-derived eicosanoids: The neglected pathway in cancer. *Cancer Metastasis Rev.* 2010, 29, 723–735, doi:10.1007/s10555-010-9264-x.

22. Wang, T.; Fu, X.; Chen, Q.; Patra, J.K.; Wang, D.; Wang, Z.; Gai, Z. Arachidonic Acid Metabolism and Kidney Inflammation. *Int. J. Mol. Sci.* 2019, 20, 3683, doi:10.3390/ijms20153683.

23. Zhu, Q.; Liang, X.; Dai, J.; Guan, X. Prostaglandin transporter, SLCO2A1, mediates the invasion and apoptosis of lung cancer cells via PI3K/AKT/mTOR pathway. *Int. J. Clin. Exp. Pathol.* 2015, 8, 9175–9181.

24. Xun, C.Q.; Ensor, C.M.; Tai, H.H. Regulation of synthesis and activity of NAD(+) dependent 15-hydroxy-prostaglandin dehydrogenase (15-PGDH) by dexamethasone and phorbol ester in human erythroleukemia (HEL) cells. *Biochem. Biophys. Res. Commun.* 1991, 177, 1258–1265, doi:10.1016/0006-291X(91)90677-y.

25. Moreno, J.J. Eicosanoid receptors: Targets for the treatment of disrupted intestinal epithelial homeostasis. *Eur. J. Pharmacol.* 2017, 796, 7–19, doi:10.1016/j.ejphar.2016.12.004.

26. Clasadonte, J.; Poulain, P.; Hanchate, N.K.; Corfas, G.; Ojeda, S.R.; Prevot, V. Prostaglandin E2 release from astrocytes triggers gonadotropin-releasing hormone (GnRH) neuron firing via EP2 receptor activation. *Proc. Natl. Acad. Sci. USA* 2011, 108, 16104–16109, doi:10.1073/pnas.1107533108.

27. Jones, R.L. Functions of prostaglandins. *Pathobiol. Annu.* 1972, 2, 359–380.

28. Lupulescu, A. Prostaglandins, their inhibitors and cancer. *Prostaglandins Leukot. Essent. Fatty Acids* 1996, 54, 83–94, doi:10.1016/s0952-3278(96)90064-2.

29. Sharma, S.; Sharma, S.C. An update on eicosanoids and inhibitors of cyclooxygenase enzyme systems. *Indian J. Exp. Biol.* 1997, 35, 1025–1031.

30. Kerola, M.; Vuolteenaho, K.; Kosonen, O.; Kankaanranta, H.; Sarna, S.; Moilanen, E. Effects of nimesulide, acetylsalicylic acid, ibuprofen and nabumetone on cyclooxygenase-1- and cyclooxygenase-2-mediated prostanoid production in healthy volunteers ex vivo. *Basic Clin. Pharmacol. Toxicol.* 2009, 104, 17–21, doi:10.1111/j.1742-7843.2008.00332.x.

31. Summ, O.; Evers, S. Mechanism of action of indomethacin in indomethacin-responsive headaches. *Curr. Pain Headache Rep.* 2013, 17, 327, doi:10.1007/s11916-013-0151-x.

32. Zarghi, A.; Arfaei, S. Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships. *Iran. J. Pharm. Res.* 2011, 10, 655–683.

33. Kim, D.; Garza, L.A. A new target for squamous cell skin cancer? *Exp. Dermatol.* 2015, 24, 14–15, doi:10.1111/exd.12576.

34. Lai, Y.H.; Liu, H.; Chiang, W.F.; Chen, T.W.; Chu, L.J.; Yu, J.S.; Chen, S.J.; Chen, H.C.; Tan, B.C. MiR-31-5p-AOX1 Axis Enhances Tumorigenic Fitness in Oral Squamous Cell Carcinoma Via the Promigratory Prostaglandin E2. *Theranostics* 2018, 8, 486–504, doi:10.7150/thno.22059.

35. Bie, Q.; Dong, H.; Jin, C.; Zhang, H.; Zhang, B. 15d-PGJ2 is a new hope for controlling tumor growth. *Am. J. Transl. Res.* 2018, 10, 648–658.

36. Gomes, R.N.; Felipe da Costa, S.; Colquhoun, A. Eicosanoids and cancer. *Clinics (Sao Paulo)* 2018, 73, e530s, doi:10.6061/clinics/2018/e530s.

37. Kiraly, A.J.; Soliman, E.; Jenkins, A.; Van Dross, R.T. Apigenin inhibits COX-2, PGE2, and EP1 and also initiates terminal differentiation in the epidermis of tumor bearing mice. *Prostaglandins Leukot. Essent. Fatty Acids* 2016, 104, 44–53, doi:10.1016/j.prolefa.2015.11.006.

38. Campione, E.; Paterno, E.J.; Candi, E.; Falconi, M.; Costanza, G.; Diluvio, L.; Terrinoni, A.; Bianchi, L.; Orlandi, A. The relevance of piroxicam for the prevention and treatment of nonmelanoma skin cancer and its precursors. *Drug Des. Devel. Ther.* 2015, 9, 5843–5850, doi:10.2147/DDDT.S84849.
39. Thyagarajan, A.; Saylaj, J.; Sahu, R.P. Acetylsalicylic acid inhibits the growth of melanoma tumors via SOX2-dependent-PAF-R-independent signaling pathway. *Oncotarget* 2017, 8, 49959–49972, doi:10.18632/oncotarget.18326.

40. Wu, J.C.; Tsai, H.E.; Hsiao, Y.H.; Wu, J.S.; Wu, C.S.; Tai, M.H. Topical MTII Therapy Suppresses Melanoma through PTEN Upregulation and Cyclooxygenase II Inhibition. *Int. J. Mol. Sci.* 2020, 21, 681, doi:10.3390/ijms21020681.

41. Zhou, M.; Wang, A.; Yin, B.; Wu, D.; Han, S.; Zhang, W.; Liu, J.; Sun, K. SND1 promotes the proliferation of osteosarcoma cells by upregulating COX2/PGE2 expression via activation of NF-kB. *Oncol. Rep.* 2019, 41, 579–589, doi:10.3892/or.2018.6822.

42. Niu, J.C.; Ma, N.; Liu, W.; Wang, P.J. EP1 receptor is involved in prostaglandin E2-induced osteosarcoma growth. *Bosn. J. Basic Med. Sci.* 2019, 19, 265–273, doi:10.17305/bjams.2019.4177.

43. Nour Eldin, E.E.M.; Nour Eldein, M.M.; Al-Readi, M.Z.; Mirza, A.A.; Fatani, S.H.; Al-Amodi, H.S.; Althubiti, M.A.; Al-Ezzi, E.M.; Eid, S.Y.; Kamel, H.F.M. Evaluation of the Diagnostic and Predicative Values of 8-Isoprostaglandin F2α as a Biomarker of Breast Cancer. *Oncol. Res. Treat.* 2020, 43, 506–517, doi:10.1159/000509671.

44. Yiannakopoulou, E. Aspirin and NSAIDs for breast cancer chemoprevention. *Eur. J. Cancer Prev.* 2015, 24, 416–421, doi:10.1097/CEJ.0000000000000098.

45. Yoda, T.; Kikuchi, K.; Miki, Y.; Onodera, Y.; Hata, S.; Takagi, K.; Nakamura, Y.; Hirakawa, H.; Ishida, T.; Suzuki, T.; et al. 11β-Prostaglandin F2α, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer. *Mol. Cell Endocrinol.* 2015, 413, 236–247, doi:10.1016/j.mce.2015.07.008.

46. Suh, J.; Kim, D.H.; Kim, E.H.; Park, S.A.; Park, J.M.; Jang, J.H.; Kim, S.J.; Na, H.K.; Kim, N.D.; Kim, N.J.; et al. 15-Deoxy-Delta(12,14)-prostaglandin J2 activates PI3K-Akt signaling in human breast cancer cells through covalent modification of the tumor suppressor PTEN. *Cancer Lett.* 2018, 424, 30–45, doi:10.1016/j.canlet.2018.03.016.

47. Olesch, C.; Sha, W.; Angioni, C.; Sha, L.K.; Acaf, E.; Patrignani, P.; Jakobsson, P.J.; Radeke, H.H.; Grosch, S.; Geisslinger, G.; et al. MPGES-1-derived PGE2 suppresses CD80 expression on tumor-associated phagocytes to inhibit anti-tumor immune responses in breast cancer. *Oncotarget* 2015, 6, 10284–10296, doi:10.18632/oncotarget.3581.

48. Pennock, N.D.; Martinson, H.A.; Guo, Q.; Betts, C.B.; Jindal, S.; Tsujikawa, T.; Coussens, L.M.; Borges, V.F.; Schedin, P. Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. *J. Immunother. Cancer* 2018, 6, 98, doi:10.1186/s40425-018-0406-y.

49. Shaashua, L.; Shabt-Simon, M.; Haldar, R.; Matzner, P.; Zmora, O.; Shabtai, M.; Sharon, E.; Allweis, T.; Barshack, I.; Hayman, L.; et al. Perioperative COX-2 and β-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial. *Clin. Cancer Res.* 2017, 23, 4651–4661, doi:10.1158/1078-0432.CCR-17-0152.

50. Choi, J.; Suh, J.Y.; Kim, D.H.; Na, H.K.; Surh, Y.J. 15-Deoxy-Delta(12,14)-prostaglandin J2 Induces Epithelial-to-mesenchymal Transition in Human Breast Cancer Cells and Promotes Fibroblast Activation. *J. Cancer Prev.* 2020, 25, 152–163, doi:10.15430/JCP.2020.25.3.152.

51. De Paz Linares, G.A.; Opperman, R.M.; Majumder, M.; Lala, P.K. Prostaglandin E2 Receptor 4 (EP4) as a Therapeutic Target to Impede Breast Cancer-Associated Angiogenesis and Lymphangiogenesis. *Cancers (Basel)* 2021, 13, 942, doi:10.3390/cancers13050942.

52. Saliaikoura, I.; Reynoso-Moreno, I.; Pozzato, C.; Rossi Sebastiano, M.; Galie, M.; Gertsch, J.; Konstantinidou, G. The ACSL3-LPA1 signaling drives prostaglandin synthesis in non-small cell lung cancer. *Oncogene* 2020, 39, 2948–2960, doi:10.1080/0162402X.2020.1825477.

53. Li, Y.F.; Han, C.C.; Wang, Y.; Cui, D.Q.; Luo, T.T.; Zhang, Y.W.; Ma, Y.; Wei, W. Combined PGE2 with TNF-α promotes laryngeal carcinoma progression by enhancing GRK2 and TRAF2 interaction. *Neoplasma* 2020, 67, 354–363, doi:10.4149/neo_2019_190256N463.

54. Cao, C.; Gao, R.; Zhang, M.; Melzio, A.L.; Fallahi, M.; Chen, Z.; Gu, Y.; Hu, C.; Welsh, E.A.; Engel, B.E.; et al. Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancer. *J. Natl. Cancer Inst.* 2015, 107, 358, doi:10.1093/jnci/dju358.

55. Saul, M.J.; Baumann, I.; Bruno, A.; Emmerich, A.C.; Wellstern, J.; Ottinger, S.M.; Contursi, A.; Dovizio, M.; Donnini, S.; Tacconelli, S.; et al. miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by miPGE2-1 induction. *FASEB J.* 2019, 33, 6933–6947, doi:10.1096/fj.201802547r.

56. Li, H.Y.; McSharry, M.; Walker, D.; Johnson, A.; Kwak, J.; Bullock, B.; Neuwelt, A.; Poczobutt, J.M.; Sippel, T.R.; Keith, R.L.; et al. Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II. *Oncology* 2018, 7, e1423182, doi:10.1080/2162402X.2017.1423182.

57. Pawitan, Y.; Yin, L.; Setiawan, A.; Auer, G.; Smedby, K.E.; Czene, K. Distinct effects of anti-inflammatory and anti-thrombotic drugs on cancer characteristics at diagnosis. *Eur. J. Cancer* 2015, 51, 751–757, doi:10.1016/j.ejca.2015.02.004.

58. Price, N.; Belani, C.P.; Jain, V.K. Cyclooxygenase-2 inhibitors as chemopreventive agents in lung cancer. *Clin. Lung Cancer* 2004, 5, 333–336, doi:10.1016/s1525-7304(11)70183-8.

59. Xu, Y.; Zhao, W.; Xu, J.; Li, J.; Hong, Z.; Yin, Z.; Wang, X. Activated hepatic stellate cells promote liver cancer by induction of myeloid-derived suppressor cells through cyclooxygenase-2. *Oncotarget* 2016, 7, 8866–8878, doi:10.18632/oncotarget.6839.

60. Martin-Sanz, P.; Casado, M.; Bosca, L. Cyclooxygenase 2 in liver dysfunction and carcinogenesis: Facts and perspectives. *World J. Gastroenterol.* 2017, 23, 3572–3580, doi:10.3748/wjg.v23.i20.3572.

61. Chen, Z.; Chen, Y.; Peng, L.; Wang, X.; Tang, N. 2,5-dimethylciclocoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1. *J. Immunother. Cancer* 2020, 8: e001377, doi:10.1136/jitc-2020-001377.
79. Nagaraju, G.P.; El-Rayes, B.F. Cyclooxygenase-2 in gastrointestinal malignancies. *Cancer* 2019, 125, 1221–1227, doi:10.1002/cncr.32010.

80. Li, Y.; Li, J.; Dong, J.; Zhang, L.; Liu, D.; He, J.; She, Y.; Ma, C.; Liu, Y. 15-PGDH Expression in Gastric Cancer: A Potential Role in Anti-Tumor Immunity. *Cancer Manag. Res.* 2020, 12, 7419–7426, doi:10.2147/CMAR.S245726.

81. Nanda, N.; Dhawan, D.K. Role of Cyclooxygenase-2 in colorectal cancer patients. *Front. Biosci. (Landmark Ed.)* 2021, 26, 706–716.

82. Schumacher, Y.; Aparicio, T.; Ourabah, S.; Baraille, F.; Martin, A.; Wind, P.; Dentin, R.; Postic, C.; Guilmeau, S. DysregulatedCRT1 activity is a novel component of PGE2 signaling that contributes to colon cancer growth. *Oncogene* 2016, 35, 2602–2614, doi:10.1038/onc.2015.283.

83. Zhang, Z.; Zheng, F.; Yu, Z.; Hao, J.; Chen, M.; Yu, W.; Guo, W.; Chen, Y.; Huang, W.; Duan, Z.; et al. XRC5 cooperates with p300 to promote cyclooxygenase-2 expression and tumor growth in colon cancers. *PLoS ONE* 2017, 12, e0186900, doi:10.1371/journal.pone.0186900.

84. Singh Ranger, G. The role of aspirin in colorectal cancer chemoprevention. *Crit. Rev. Oncol. Hematol.* 2016, 104, 87–90, doi:10.1016/j.critrevonc.2016.05.011.

85. Gottschall, H.; Schmocker, C.; Hartmann, D.; Rohwer, N.; Rund, K.; Kutzner, L.; Nolte, F.; Ostermann, A.I.; Schebb, N.H.; Weylandt, K.H. Aspirin alone and combined with a statin suppresses eicosanoid formation in human colon tissue. *J. Lipid Res.* 2018, 59, 864–871, doi:10.1194/jlr.M078725.

86. Fink, S.P.; Dawson, D.M.; Zhang, Y.; Kresak, A.; Lawrence, E.G.; Yang, P.; Chen, Y.; Barnholtz-Sloan, J.S.; Willis, J.E.; Kopelovich, L.; et al. Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs. *Carcinogenesis* 2015, 36, 291–298, doi:10.1039/carcin/bgu241.

87. Kapral, M.; Wawszczzyk, J.; Sosnicki, S.; Jesse, K.; Weglarz, L. Modulating effect of inositol hexaphosphate on arachidonic acid-dependent pathways in colon cancer cells. *Prostaglandins Other Lipid Mediat.* 2017, 131, 41–48, doi:10.1016/j.prostaglandins.2017.08.002.

88. Chang, H.H.; Young, S.H.; Sinnett-Smith, J.; Chou, C.E.; Moro, A.; Hertzer, K.M.; Hines, O.J.; Rozengurt, E.; Eibl, G. Prostaglandin E2 activates the mTORC1 pathway through an EP4/cAMP/PKA- and EP1/Ca2+-mediated mechanism in the human pancreatic carcinoma cell line Panc-1. *Am. J. Physiol. Cell Physiol.* 2015, 309, C639–C649, doi:10.1152/ajpcell.00417.2014.

89. Stamatakis, K.; Jimenez-Martinez, M.; Jimenez-Segovia, A.; Chico-Calero, I.; Conde, E.; Galan-Martinez, J.; Ruiz, J.; Pascual, A.; Barrocal, B.; Lopez-Perez, R.; et al. Prostaglandins induce early growth response 1 transcription factor mediated microsomal prostaglandin E2 synthase up-regulation for colorectal cancer progression. *OncoTarget* 2015, 6, 39941–39959, doi:10.18632/oncotarget.5402.

90. Altobelli, E.; Angeletti, P.M.; Latella, G. Role of Urinary Biomarkers in the Diagnosis of Adenoma and Colorectal Cancer: A Systematic Review and Meta-Analysis. *J. Cancer* 2016, 7, 1984–2004, doi:10.7150/jca.16244.

91. Mizuno, R.; Kawada, K.; Sakai, Y. Prostaglandin E2/EP Signaling in the Tumor Microenvironment of Colorectal Cancer. *Int. J. Mol. Sci.* 2019, 20, 6254, doi:10.3390/ijms20246254.

92. Gorchs, L.; Ahmed, S.; Mayer, C.; Knauf, A.; Fernandez Moro, C.; Svensson, M.; Heuchel, R.; Rangelova, E.; Bergman, P.; Kape, H. The vitamin D analogue calcipotriol promotes an anti-tumorigenic phenotype of human pancreatic CAFs but reduces T cell mediated immunity. *Sci. Rep.* 2020, 10, 17144, doi:10.1038/s41598-020-74368-3.

93. Shi, H.; Sun, X.; Kong, A.; Ma, H.; Xie, Y.; Cheng, D.; Wong, C.K.C.; Zhou, Y.; Gu, J. Cadmium induces epithelial-mesenchymal transition and migration of renal cancer cells by increasing PGE2 through a cAMP/PKA-COX2 dependent mechanism. *Biomed. Pharmacother.* 2020, 127, 109531, doi:10.1016/j.biopharma.2020.109531.

94. Verratti, V.; Brunetti, L.; Ferrante, C.; Orlando, G.; Recinella, L.; Chiavaroli, A.; Leone, S.; Wang, R.; Berardinelli, F. Physiological and pathological levels of prostaglandin E2 in renal parenchyma and neoplastic renal tissue. *Prostaglandins Other Lipid Mediat.* 2019, 141, 11–13, doi:10.1016/j.prostaglandins.2019.02.004.

95. Woolbright, B.L.; Pilbeam, C.C.; Taylor, J.A., 3rd. Prostaglandin E2 as a therapeutic target in bladder cancer: From basic science to clinical trials. *Prostaglandins Other Lipid Mediat.* 2020, 148, 106409, doi:10.1016/j.prostaglandins.2020.106409.

96. Larsson, K.; Kock, A.; Kogner, P.; Jakobsson, P.J. Targeting the COX/mPGES-1/PGE2 Pathway in Neuroblastoma. *Adv. Exp. Med. Biol.* 2019, 1161, 89–100, doi:10.1007/978-3-030-21735-8_9.

97. Pozzoli, G.; Marei, H.E.; Althani, A.; Boninsegna, A.; Casalbore, P.; Marlier, L.; Lanzilli, G.; Zonfrillo, M.; Petrucci, G.; Rocca, B.; et al. Aspirin inhibits cancer stem cells properties and growth of glioblastoma multiforme through Rb1 pathway modulation. *J. Cell Physiol.* 2019, 9, 15459–15471, doi:10.1002/jcp.28194, doi:10.1002/jcp.28194.

98. Zhang, J.; He, J.; Zhang, L. The down-regulation of microRNA-137 contributes to the up-regulation of retinoblastoma cell proliferation and invasion by regulating COX-2/PGE2 signaling. *Biomed. Pharmacother.* 2018, 106, 35–42, doi:10.1016/j.biopha.2018.06.099.

99. Colquhoun, A. Cell biology-metabolic crosstalk in glioma. *Int. J. Biochem. Cell Biol.* 2017, 89, 171–181, doi:10.1016/j.biocel.2017.05.022.

100. Ochs, K.; Ott, M.; Rauschenbach, K.J.; Deumelantd, K.; Sahm, F.; Opitz, C.A.; von Deimling, A.; Wick, W.; Platten, M. Triptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4. *J. Neurochem.* 2016, 136, 1142–1154, doi:10.1111/jnc.13503.

101. Pandey, V.K.; Amin, P.J.; Shankar, B.S. COX-2 inhibitor prevents tumor induced down regulation of classical DC lineage specific transcription factor Zbtb46 resulting in immunocompetent DC and decreased tumor burden. *Immunol. Lett.* 2017, 184, 23–33, doi:10.1016/j.imlet.2017.01.019.
85. Sperandio, M.; Demasi, A.P.D.; Martinez, E.F.; Saad, S.O.; Pericole, F.V.; Vieira, K.P.; Freitas, N.S.; Araujo, V.C.; Brown, A.L.; Clemente-Napimoga, J.T.; et al. 15d-PGJ2 as an endoplasmic reticulum stress manipulator in multiple myeloma in vitro and in vivo. Exp. Mol. Pathol. 2017, 102, 434–445, doi:10.1016/j.yexmp.2017.05.003.

86. Richartz, N.; Duthil, E.; Ford, A.; Naderi, E.H.; Bhagwat, S.; Gilljam, K.M.; Burman, M.M.; Ruud, E.; Blomhoff, H.K.; Skah, S. Targeting cyclooxygenase by indomethacin decelerates progression of acute lymphoblastic leukemia in a xenograft model. Blood Adv. 2019, 3, 3181–3190, doi:10.1182/bloodadvances.201900473.

87. Roderick, J.E.; Gallagher, K.M.; Murphy, L.C.; O’Connor, K.W.; Tang, K.; Zhang, B.; Brehm, M.A.; Greiner, D.L.; Yu, J.; Zhu, L.J.; et al. Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death. Blood 2021, 137, 500–512, doi:10.1182/blood.2020005712.

88. Finch, E.R.; Tukaramrao, D.B.; Goodfield, L.L.; Quickel, M.D.; Paulson, R.F.; Prabhu, K.S. Activation of PPARGamma by endogenous prostaglandin J2 mediates the antileukemic effect of selenium in murine leukemia. Blood 2017, 129, 1802–1810, doi:10.1182/blood-2016-08-736405.

89. Akbari, N.; Ghorbani, M.; Salimi, V.; Alimohammadi, A.; Khamseh, M.E.; Akbari, H.; Nourbakhsh, M.; Sheikhi, A.; Taghavi, S.F.; Tavakoli-Yaraki, M. Cyclooxygenase enzyme and PGE2 expression in patients with functional and non-functional pituitary adenomas. BMC Endocr. Disord. 2020, 20, 39, doi:10.1186/s12902-020-01515-8.

90. Parvathareddy, S.K.; Siraj, A.K.; Annaiyappanaidu, P.; Al-Sobhi, S.S.; Al-Dayel, F.; Al-Kuraya, K.S. Prognostic Significance of COX-2 Overexpression in BRAF-Mutated Middle Eastern Papillary Thyroid Carcinoma. Int. J. Mol. Sci. 2020, 21, 9498, doi:10.3390/ijms21249498.

91. Santoro, A.; Bufo, P.; Russo, G.; Cagiano, S.; Papagerakis, S.; Bucci, P.; Aquino, G.; Longo, F.; Feola, A.; Giordano, A.; et al. Link between chronic inflammation and human papillomavirus-induced carcinogenesis (Review). Oncotarget 2016, 7, 48050–48058, doi:10.18632/oncotarget.10347.

92. Frejborg, E.; Salo, T.; Salem, A. Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis. Int. J. Mol. Sci. 2020, 21, 9246, doi:10.3390/ijms21239247.

93. Angulo, J.; Cuevas, P.; Cuevas, B.; El Youssef, M.; Fernandez, A.; Martinez-Salamanca, E.; Gonzalez-Corrochano, R.; Gimenez-Gallego, G. Dicacytyloxygenase expression and clinical implication of cyclooxygenase-2 and E-cadherin in oral squamous cell carcinomas. Cancer Biol. Ther. 2020, 21, 667–674, doi:10.1080/15384047.2015.1071741.

94. Parida, S.; Parekh, A.; Dey, G.; Ghosh, S.C.; Mandal, M. Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model. Cancer Biol. Ther. 2015, 16, 922–932, doi:10.1080/15384047.2015.1040953.

95. Angulo, J.; Cuevas, P.; Cuevas, B.; El Youssef, M.; Fernandez, A.; Martinez-Salamanca, E.; Gonzalez-Corrochano, R.; Gimenez-Gallego, G. Dicacytyloxy derivatization of the fibroblast growth factor inhibitor dobesilate enhances its anti-inflammatory, anti-angiogenic and anti-tumoral activities. J. Transl. Med. 2015, 13, 48, doi:10.1186/s12967-015-0413-4.

96. Zhang, Y.; Tighe, S.; Zhu, Y.T. COX-2 Signaling in the Tumor Microenvironment. Adv. Exp. Med. Biol. 2020, 1277, 87–104, doi:10.1007/978-3-030-50224-9_6.

97. Rakesh, K.S.; Jagdish, S.; Balaji, K.S.; Zameer, F.; Swaroop, T.R.; Mohan, C.D.; Jayarama, S.; Rangappa, K.S. 3,5-Disubstituted Isoxazole Derivatives: Potential Inhibitors of Inflammation and Cancer. Inflammation 2016, 39, 269–280, doi:10.1007/s10753-015-0247-5.
107. Sharma, S.; Kalra, H.; Akundi, R.S. Extracellular ATP Mediates Cancer Cell Migration and Invasion through Increased Expression of Cyclooxygenase 2. *Front. Pharmacol.* **2020,** 11, 617211, doi:10.3389/fphar.2020.617211.

108. Wu, X.; Hu, W.; Lu, L.; Zhao, Y.; Zhou, Y.; Xiao, Z.; Zhang, L.; Zhang, H.; Li, X.; Li, W.; et al. Repurposing vitamin D for treatment of human malignancies via targeting tumor microenvironment. *Acta Pharm. Sin. B* **2019,** 9, 203–219, doi:10.1016/j.apsb.2018.09.002.

109. Almeida, E.B.; Silva, K.P.H.; Paixao, V.; Amaral, J.B.D.; Rossi, M.; Xavier-Navarro, R.A.; Barros, K.V.; Silveira, V.L.F.; Vieira, R.P.; Oliveira, L.V.F.; et al. A Mixture of Polyunsaturated Fatty Acids omega-3 and omega-6 Reduces Melanoma Growth by Inhibiting Inflammatory Mediators in the Murine Tumor Microenvironment. *Int. J. Mol. Sci.* **2019,** 20, 3765, doi:10.3390/ijms20153765.

110. Knights, K.M.; Mangoni, A.A.; Miners, J.O. Defining the COX inhibitor selectivity of NSAIDs: Implications for understanding toxicity. *Expert Rev. Clin. Pharmacol.* **2010,** 3, 769–776, doi:10.1586/ecp.10.120.

111. Li, S.; Jiang, M.; Wang, L.; Yu, S. Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: Recent advancement. *Biomed. Pharmacother.* **2020,** 129, 110389, doi:10.1016/j.biopha.2020.110389.

112. Jang, H.Y.; Hong, O.Y.; Youn, H.J.; Kim, M.G.; Kim, C.H.; Jung, S.H.; Kim, J.S. 15d-PGJ2 inhibits NF-κB and AP-1-mediated MMP-9 expression and invasion of breast cancer cell by means of a heme oxygenase-1-dependent mechanism. *MBB Rep.* **2020,** 53, 212–217.

113. Takahashi, R.; Amano, H.; Ito, Y.; Eshima, K.; Satoh, T.; Iwamura, M.; Nakamura, M.; Kitasato, H.; Uematsu, S.; Raouf, J.; et al. Microsomal prostaglandin E synthase-1 promotes lung metastasis via SDF-1/CXCR4-mediated recruitment of CD11b(+)Gr1(+)MDSCs from bone marrow. *Biomed. Pharmacother.* **2020,** 121, 109581, doi:10.1016/j.biopha.2019.109581.

114. Wu, K.; Fukuda, K.; Xing, F.; Zhang, Y.; Sharma, S.; Liu, Y.; Chan, M.D.; Zhou, X.; Qasem, S.A.; Pochampally, R.; et al. Roles of the cyclooxygenase 2 matrix metalloproteinase 1 pathway in brain metastasis of breast cancer. *J. Biol. Chem.* **2015,** 290, 9842–9854, doi:10.1074/jbc.M114.602185.

115. Kanikarla-Marie, P.; Kopetz, S.; Hawk, E.T.; Millward, S.W.; Sood, A.K.; Gresele, P.; Overman, M.; Honn, K.; Menter, D.G. Bioactive lipid metabolism in platelet “first responder” and cancer biology. *Cancer Metastasis Rev.* **2018,** 37, 439–454, doi:10.1007/s10555-018-9755-8.

116. Sorski, L.; Melamed, R.; Matzner, P.; Lavon, H.; Shaashua, L.; Rosenne, E.; Ben-Eliyahu, S. Reducing liver metastases of colon cancer in the context of extensive and minor surgeries through β-adrenoceptors blockade and COX2 inhibition. *Brain Behav. Immun.* **2016,** 58, 91–98, doi:10.1016/j.bbi.2016.05.017.

117. Ye, Y.; Peng, L.; Vattai, A.; Deuster, E.; Kuhn, C.; Dannecker, C.; Mahner, S.; Jeschke, U.; von Schonfeldt, V.; Heidegger, H.H. Prostaglandin E2 receptor 3 (EP3) signaling promotes migration of cervical cancer via urokinase-type plasminogen activator receptor (uPAR). *J. Cancer Res. Clin. Oncol.* **2020,** 146, 2189–2203, doi:10.1007/s00432-020-03272-0.

118. Porta, C.; Consonni, F.M.; Morlachiti, S.; Sangaletti, S.; Bleve, A.; Totoaro, M.G.; Larghi, P.; Rimoldi, M.; Tripodo, C.; Strauss, L.; et al. Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs. *Cancer Res.* **2020,** 80, 2874–2888, doi:10.1158/0008-5472.CAN-19-2843.

119. Wang, S.J.; Khullar, K.; Kim, S.; Yegya-Raman, N.; Malhotra, J.; Groisberg, R.; Crayton, S.H.; Silk, A.W.; Nosher, J.L.; Gentile, M.A.; et al. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer. *J. Immunother. Cancer* **2020,** 8:e000889, doi:10.1136/jitc-2020-000889.

120. Markosyan, N.; Li, J.; Sun, Y.H.; Richman, L.P.; Lin, J.H.; Yan, F.; Quinones, L.; Sela, Y.; Yamazoe, T.; Gordon, N.; et al. Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2). *J. Clin. Invest.* **2019,** 129, 3594–3609, doi:10.1172/JCI127755.

121. Veglia, F.; Tyririn, V.A.; Blasi, M.; De Leo, A.; Kossenkov, A.V.; Donthireddy, L.; To, T.K.J.; Schug, Z.; Basu, S.; Wang, F.; et al. Fatty acid transport protein 2 reprograms neutrophils in cancer. *Nature* **2019,** 569, 73–78, doi:10.1038/s41586-019-1118-2.

122. Roulis, M.; Kaklamanos, A.; Schernthanner, M.; Bielecki, P.; Zhao, J.; Kaffe, E.; Frommelt, L.S.; Qu, R.; Knapp, M.S.; Henries, A.; et al. Paracrine orchestration of intestinal tumorigenesis by a mesenchymal niche. *Nature* **2020,** 580, 524–529, doi:10.1038/s41586-020-2166-3.